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Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate at 8%. 
Since targeting KRAS, the driver oncogene in PDAC, has not been a clinically successful 
endeavor to date and given that the growth of pancreatic tumors is intricately linked to 
reactive oxygen species (ROS) detoxification mechanisms, perturbation of oxidative 
balance might be an effective therapeutic strategy. A major intracellular antioxidant is 
glutathione (GSH), a tripeptide made of glycine, glutamate and cysteine. Cysteine (L-Cys), 
which has the functional moiety of GSH, can either be synthesized de novo intracellularly 
or imported, predominantly as cystine (CSSC) that is reduced intracellularly to L-Cys. 
Recently, our group has engineered a human enzyme called cyst(e)inase that degrades both 
extracellular L-Cys and CSSC and is a safe and effective therapeutic agent for multiple 
cancer models. 
In our study with three pancreatic cancer cell lines, we found that even though 
cyst(e)inase depleted intracellular L-Cys and GSH in all three, only one “sensitive” cell 




lines were able to arrest their growth and maintain survival. Further mechanistic 
exploration showed that only the resistant cell lines were capable of maintaining 
mitochondrial fitness during L-Cys/CSSC depletion. Since resistance seemed predicated 
on maintenance of functional mitochondria, a major ROS producer, we sought to sensitize 
the resistant cells to cyst(e)inase by concurrently inhibiting other antioxidant pathways. As 
expected, this approach led to synergistic inhibition of cell survival in all three cell lines 
with the most striking effect and high translational potential provided by auranofin, a 
thioredoxin reductase inhibitor and an approved drug for rheumatoid arthritis. Treatment 
of cyst(e)inase and auranofin in combination caused a synergistic increase in mitochondrial 
ROS and apoptosis, and also led to inhibition of mitophagy – a cellular mechanism for 
mitochondrial quality control. Treatment of nude mice harboring pancreatic cancer 
xenografts recapitulated these results: auranofin sensitized the completely resistant cell line 
to cyst(e)inase without causing any systemic toxicity. Our data provides strong rationale to 
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Chapter 1: Introduction 
1.1 Background: Pancreatic cancer and its vulnerabilities 
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that continues to 
have a very low 5-year survival rate (8%) despite our increased understanding of the 
underlying cancer biology and improved ability to perform complex surgical procedures1,2. 
One major reason for this is that over 80% of patients present at a stage when surgical 
resection is no longer possible. They are then at the mercy of chemotherapy, most of which 
provide a median survival increase of about half a year and are associated with many 
toxicities2. To improve survival and quality of life for PDAC patients, new agents that are 
more effective and less toxic need to be discovered. 
One of the most defining features of pancreatic adenocarcinoma is activating 
mutations (>90%) in the KRAS gene3, which is thought to be the major oncogenic driver 
with subsequent mutations in other tumor suppressors serving as bottlenecks for tumor 
progression to adenocarcinoma.  Genetically engineered mouse models also show a similar 
genetic progression providing a platform to more accurately study this phenomenon4.  
Mounting evidence suggests that the major oncogenic mutation in the Kras protein in 
pancreatic cancer is a substitution at the 12th position from a glycine to aspartate 
(KrasG12D). More recently, knock-in models and doxycycline induced silencing of KRAS 
in genetically engineered mouse models have uncovered crucial dependencies – loss of 




models5,6. Although KRAS extinction in vitro and in genetic mouse models can inhibit 
growth of human PDAC cell lines in some contexts, clinical efforts at targeting 
downstream components of RAS-MAPK (mitogen activated protein kinase) pathway have 
not been very successful to date. Furthermore, some have even reported a subset of 
pancreatic cancer cells that are resistant to KRAS ablation, and are in fact, more tumorigenic 
due to the presence of stem-like features7,8. Hence, identifying other vulnerable pathways 
in pancreatic cancer might provide a more effective therapeutic approach.  
1.2 Metabolic requirements of cell proliferation 
Unicellular organisms face intense evolutionary pressure to assimilate available 
nutrients into biomass and proliferate as quickly as possible. They have evolved their 
metabolic machinery to direct available carbon, nitrogen and free energy into pathways 
that lead to the production of a new cell. On the other hand, when nutrients become scarce, 
they need to extract the maximum possible free energy from available resources to maintain 
survival9. This dichotomy can be conceptualized with a real-world human example. 
Suppose, a tribal person who is living in the forest has access to some wood and is faced 
with the decision of how to make the best use of this resource. If he is facing this situation 
during the summer when vegetation is plentiful and food is readily available, he might use 
this wood to make a house for shelter, and even make an encircling fence (biomass 
accumulation). However, if he arrives at this decisional crossroad during the winter time 
when preservation of body heat becomes an extra survival task, and the scarcity of 




for making fire (energy generation). Similarly, the decision faced by unicellular as well as 
mammalian cells to whether proliferate or maintain survival imposes the need to channel 
available substrates through distinct metabolic routes. Consequently, regulatory 
mechanisms have evolved in organisms spanning almost all branches of life to control 
cellular metabolism as a function of nutrient availability which, in turn, guides the decision 
to whether proliferate or not10.    
In multicellular organisms, most cells have a constant access to nutrients and are 
therefore not limited by nutrient availability for proliferation. In fact, survival of the 
organism is dependent upon prevention of unrestrained proliferation of individual cells. 
This is ensured by mammalian cells through signaling mechanisms that allow uptake of 
nutrients and subsequent intracellular utilization only when instructed to do so by growth 
factors. Cancer cells overcome this dependence on growth factor signaling through genetic 
mutations which allows them uptake nutrients, particularly glucose and glutamine, and 
orchestrate their metabolism in a manner that is conducive to proliferation. 
 1.2.1 The Warburg Effect: Implications in cellular anabolism 
The propensity of proliferating cells to metabolize glucose primarily through 
fermentation and excrete ethanol was first observed in yeast. Otto Warburg extended these 
observations to cancer cells and discovered that majority of the glucose carbon taken up by 
cancer cells is metabolized into lactate even in the presence of ample oxygen. This “aerobic 
glycolysis” seen in cancer cells, now famously known as the Warburg Effect, led Warburg 




remains one of the most enduring hallmarks of cancer metabolism, which has found clinical 
application in 18F-deoxyglucose positron emission tomography (FDG-PET) imaging. 
However, advances in cancer metabolism research over the last two decades and the 
concomitant, piling evidence that points to the importance of mitochondrial metabolism 
has made Warburg’s hypothesis of cancer cells harboring damaged mitochondria 
untenable11.  
The presence of oxygen promotes normal, non-proliferating cells (where most of 
our current understanding of metabolic pathways is derived from) to maximize their 
adenosine triphosphate (ATP) yield by completely oxidizing glucose-derived pyruvate to 
carbon dioxide in the mitochondria via the tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation. The fact that metabolism of a large portion of available glucose into 
lactate, which yields a net of 2 ATP molecules compared to the maximum of 36 ATP 
molecules produced by oxidative phosphorylation, can sustain the bioenergetic demands 
of proliferation in unicellular as well as mammalian cells implies that ATP availability is 
not a limiting factor for proliferation. ATP production is only a problem when resources 
are scarce, which is not a problem for mammalian cells as aforementioned. Moreover, 
complete oxidation of glucose carbon into CO2 runs counter to the need of a proliferating 
cell for biomass accumulation. Recent work has slowly caused a paradigm shift in the field 
which has increased the appreciation for the Warburg Effect as an effective mechanism to 
support macromolecular biosynthesis rather than viewing it as an inefficient mechanism 




Indeed, upstream metabolites of glycolysis can be shunted to important 
biosynthetic pathways. By re-routing glucose-6-phosphate into the pentose phosphate 
pathway, cancer cells can synthesize ribose-5-phosphate, which can subsequently be used 
for nucleotide synthesis. In addition, this diversion of glucose also results in the production 
of NADPH, which is very important for cells to maintain redox homeostasis (to be 
discussed later). Specifically in pancreatic cancer cells, oncogenic Kras has been shown to 
promote tumor maintenance by complementing the increased glycolysis with channeling 
of glucose substrates into hexosamine biosynthetic pathway for protein and lipid 
glycosylation, and the non-oxidative arm of the pentose phosphate pathway for nucleotide 
synthesis6. Upregulation of a specific enzyme phosphoglycerate dehydrogenase (PHGDH) 
allows the diversion of glyceraldehyde-3-phosphate towards the serine synthesis pathway, 
which is required for the maintenance of breast as well as lung cancer cells due to this 
pathway’s pleitropic roles in nucleotide, amino acid and redox metabolism13-15. Another 
notable enzyme in the glycolytic highway is pyruvate kinase, which catalyzes the 
conversion of phosphoenolpyruvate (PEP) into pyruvate with concomitant generation of 
ATP from ADP. Proliferating cells almost universally express the M2 isoform of pyruvate 
kinase (PKM2), which is less active than the normal M1 variant that is present in most 
adult differentiated tissues. This might seem paradoxical at first glance, but the lower 
enzymatic activity actually allows for the accumulation of upstream intermediates which 
can serve as biosynthetic precursors. The tumor-promoting effects of this “bottleneck” at 
PKM2 is validated by the fact that either expressing the PKM1 isoform or using small 




1.2.2 Mitochondrial metabolism in cancer 
Evidence against Warburg’s original hypothesis started to surface as early as the 
1950s showing that mitochondria in tumors and normal cells show similar oxidative 
capacity17,18. Fast-forward more than sixty years to present date, the diverse, established 
functions of the mitochondria for supporting cell proliferation seem as indispensable to 
tumor maintenance as it is to any discussion of tumor biology. Technological 
advancements have allowed us to actually quantify the oxidation of not just glucose but 
other substrates such as lactate in intact tumors in mice as well as humans19-21.  
The bioenergetic and biosynthetic functions of aerobic glycolysis are still not 
enough to satisfy a proliferating cell’s demand for proteins, nucleotides and fatty acids22. 
Many of the precursors to these macromolecules are derived from mitochondrial TCA 
cycle (Krebs cycle), which can utilize multiple carbon sources such as glucose-derived 
pyruvate, amino acids such as glutamine and fatty acids to fuel ATP synthesis as well as 
synthesis of macromolecular precursors. For example, the TCA cycle intermediate citrate, 
which is formed through condensation of oxaloacetate and acetyl-CoA by the exclusively 
mitochondrial enzyme citrate synthase, can be exported back into the cytosol and cleaved 
by ATP citrate lyase (ACL) to re-generate acetyl-CoA in the cytosol that can then fuel fatty 
acid synthesis. Inhibition of fatty acid synthesis either by inhibiting ACL or acetyl-CoA 
carboxylase (ACC), which mediates the first committed step for fatty acid synthesis, 
suppresses tumor cell growth23,24.  
Oxaloacetate is another important metabolite that can be transaminated into 




aminotransferase. Since a cell can synthesize aspartate as such, it is deemed a non-essential 
amino acid, and therefore even absent in some cell culture media formulations. However, 
since aspartate is indispensable for the synthesis of purines and pyrimidines, it is a 
requirement for cellular proliferation. As an amino acid, it is also a substrate for protein 
synthesis. In fact, a major function of the electron transport chain in proliferating cells is 
to support aspartate synthesis by maintaining the redox balance in the electron acceptor 
pool (i.e, NAD+)25,26. Growth arrest exhibited by cells that are defective in electron 
transport function can be rescued by supplementation with aspartate or by overexpression 
of the aspartate transporter25. Nucleotide and protein synthesis facilitated by aspartate is 
required for not only proliferation but also cell survival during stress conditions for the 
transcription of stress related genes and the translation of their protein products, which 
highlights the importance of aspartate in proliferative as well as quiescent metabolism. 
These observations provide a mechanistic link of how the increased reliance on oxidative 
phosphorylation during non-proliferative conditions9 meets a cell’s survival demand of 
energy production as well as basal nucleotide and protein synthesis. 
The exit of precursor molecules (cataplerosis) from the TCA cycle needs to be 
carefully balanced by the entry of such intermediates into the cycle (anaplerosis) to 
maintain cycle function. The major anaplerotic precursor in proliferating cells is glutamine, 
which is oxidized in a step-wise fashion into the TCA cycle intermediate α-ketoglutarate 
that is eventually metabolized to oxaloacetate27. Thus, many cancer cells exhibit glutamine 
addiction, to overcome which they need to upregulate alternate forms of anaplerosis, most 




glucose-derived pyruvate28,29. Even though majority of cancer cells have intact 
mitochondrial function, small subsets of cancer cells harbor inactivating mutations in the 
mitochondrial enzymes fumarate hydratase and succinate dehydrogenase. Despite having 
a premature truncation of the TCA cycle, these cells are able to maintain a proliferative 
phenotype by fulfilling their biosynthetic needs either through pyruvate carboxylation30,31 
or through reductive carboxylation of α-ketoglutarate into citrate32.   
In the context of pancreatic cancer, a subset of cells that were able to survive KRAS 
extinction were surprisingly more tumorigenic due to the upregulation of genes involving 
mitochondrial function7. Moreover, pancreatic cancer cells have an augmented ability to 
maintain oxidative metabolism due to increased autophagic flux, a process through which 
the cell recycles intracellular nutrients as well as organelles such as mitochondria33. 
1.2.3 Integration of growth-factor signaling and altered metabolism 
Activation of the PI3K/Akt signaling pathway is perhaps the most common genetic 
alteration in spontaneous human cancers. Activated PI3K/Akt causes increased glucose 
utilization by orchestrating a concerted program that features increased expression of 
glucose transporters as well as activation of glycolytic enzymes11. This oncogenic pathway 
also promotes glucose carbon flux into fatty acid synthesis by phosphorylating and 
activating ATP citrate lyase24,34.  
The well-characterized regulator of protein synthesis and cell growth, mechanistic 
target of rapamycin (mTORC1) is also downstream of Akt, and has many functions that 




glycolysis, pentose phosphate pathway, and de novo nucleotide synthesis35.  Amino acids 
are essential for mTORC1 activation but mammalian cells have nutrient sensing 
mechanisms that allow mTORC1 to gauge the levels of not only amino acids but also 
glucose and oxygen35 to send appropriate growth signals downstream.  During starvation 
conditions, inhibition of mTORC1 is mediated through the integration of multiple inputs 
i.e., from AMPK via energetic stress and from GCN2 via amino acid deprivation10,36. 
The oncogenic transcription factor Myc, which is dysregulated in multiple cancers 
also has several important metabolic roles. It stimulates transcription of nuclearly encoded 
mitochondrial genes and leads to mitochondrial biogenesis37. It is also thought to mediate 
glutamine addiction in cancer cells through upregulation of glutaminase, which deaminates 
glutamine to glutamate38. 
As such, cancer and normal cells, more or less, possess the same metabolic network 
but they differ fundamentally in how they channel available resources into different 
pathways along that network to achieve distinct goals i.e., unbridled proliferation vs 
maximum energy generation. Glycolytic metabolism and mitochondrial substrate 
oxidation are both used to different ends by the two entities. This altered metabolism, now 
considered a core hallmark in cancer, lends itself to pursuits of drug development against 
targets that provide a wide enough therapeutic window. There are several analytical 
methods to study cancer metabolism – the one that we utilize in our studies will be 




1.2.4 13C tracer methods to study cancer metabolism 
13C tracer studies have gained prominence as one of the most frequently used 
modalities in metabolic research due, in part, to their ability to trace a wide varitey of 
metabolites in a single experiment not afforded by traditional 14C tracer studies, which 
require purification, isolation, and carbon-by-carbon degradation of the metabolite of 
interest. 13C is a stable isotope of carbon, which means that a wide variety of 13C-enriched 
compounds are readily, commercially available. These compounds can be administered to 
metabolic entities (in our case, tumor cells) in the form of 13C labeled nutrients (glucose 
and/or glutamine) and the 13C distribution in different metabolites can be studied. In 
addition, the low natural abundance of 13C (1.11%) minimizes confounding variables. 
Methods have been developed which even correct for the 13C natural abuandance in such 
isotopic studies39,40. 
Mass isotopologue distribution (MID) analysis of metabolism is a method which 
studies 13C enrichment in different metabolites through mass spectrometry (MS). It usually 
follows a chromatographic separation of the different metabolites through gas 
chromatography (GC) or high performance liquid chromatography (HPLC)41. GC/MS can 
elucidate crucial information about different metabolic pathways such as glycolysis, the 
TCA cycle, and non-essential amino acid synthesis, and hence provides a great avenue to 
study metabolism. The method is sensitive enough to detect a wide range of molecules in 
a cell. A gas chromatograph separates the various metabolites in a cell based on their 
differential interaction with the stationary and the mobile phase. As they elute off the GC 
column, they are bombarded through electron impact and broken up into specific ion 
fragments, which are detected by a mass analyzer and sorted according to their mass-to-




diagnostic tool. Hence, the different peaks on the GC spectrum can be assigned to specific 
metabolites by comparing their ion fragment spectrum with that of different molecules in 
a mass spectral library. 
The extensive information about the different biochemical pathways that is 
available in the literature forms the basis for isotopologue analysis of metabolism. The 
known specifics of many metabolic reactions, which ranges from knowledge about the site 
of different reactions to the specific mechanisms that those reactions take, makes it easier 
to study the 13C enrichment in the different metabolites which allows certain level of 
inference into the metabolic routes taken by those metabolites. In our context, the reactions 
of the TCA cycle are well characterized. Knowledge of carbon transfer through the cycle 
permits one to draw up a model showing the passage of 13C label through the carbon 
backbone of different nutrients through the TCA cycle. (Illustration 1.1).  
This model provides a good starting point for mass isotopologue analysis because 
it shows how the different isotopologues could be produced when different 13C substrates 
are metabolized via distinct routes. For example, it shows how the labeling pattern in 
oxaloacetate is dependent on whether glucose or glutamine is labeled with 13C, and whether 
glucose-derived pyruvate is oxidized to acetyl-CoA by pyruvate dehydrogenase (PDH) or 
carboxylated into oxaloacetate by pyruvate carboxylase (PC). If the cells are cultured in 
uniformly 13C labeled glucose ([U-13C]-glucose, glucose labeled in all six of its carbons), 
glycolysis produces pyruvate that is universally labeled. This pyruvate is transported to the 
mitochondria, where it has two fates. If it is metabolized via PDH, the resulting 
oxaloacetate pool will have an m+2 fraction (oxaloacetate 13C-labeled in two of its carbons) 
and a lower m+4 fraction (produced if the same m+2 oxaloacetate molecule turns over 3 
times in the TCA cycle – a rare event in cancer cells due to cataplerosis). On the other 





Illustration 1.1 Schematic showing the evolution of 13C isotopologues of TCA cycle 
intermediates when glucose or glutamine is 13C labeled. 
Anaplerosis via [U-13C]-glutamine is the major source of 13C labeling in the oxaloacetate 
(OAA) pool. However, [U-13C]-glucose-derived pyruvate also contributes to some labeling 
in OAA either via oxidation into acetyl-CoA (by pyruvate dehydrogenase, PDH) and 
subsequent entry into the TCA cycle or via carboxylation into OAA (by pyruvate 
carboxylase, PC). Abbreviations: Ac-CoA, acetyl-CoA; Cit, citrate; α-KG, α-ketoglutarate; 
Succ, succinate. Blue (glucose-derived) and red (glutamine-derived) circles represent 13C 




isotopologue in the oxaloacetate pool. However, the largest fraction of isotopologue in 
oxaloacetate when the labeled substrate is glucose will be m+0 (unlabeled with 13C) 
because most of the oxaloacetate in cancer cells is normally derived from anaplerosis 
through glutamine27. Consequently, if cells are cultured in [U-13C]-glutamine, the major 
isotopologue in the oxaloacetate pool (and subsequently aspartate) will be m+4.  
In our study, we will use this framework to conduct isotopologue analysis primarily 
with [U-13C]-glucose as we explore the metabolic differences between different pancreatic 
cancer cell lines.   
1.3 Opening a therapeutic window by perturbing oxidative balance  
Cancer cells in general are known to have elevated production of reactive oxygen 
species (ROS). As aforementioned, a necessary requirement for proliferating cells is the 
synthesis of aspartate through the maintenance of a functional electron transport chain 
(ETC). Since majority of the ROS is produced by the ETC through incomplete transfer of 
electrons, cancer cells have a greater liability to combat toxic accumulation of ROS42.  
At moderate levels however, ROS actually promote tumorigenesis by inducing 
growth promoting pathways such as phosphorylation of MAPKs and extracellular signal-
regulated kinase (ERK), and by inhibiting tumor suppressors such as phosphate and tensin 
homolog (PTEN) and protein tyrosine phosphatases43-45. Reactive oxygen species 
production has been shown to be a requirement for Kras-mediated tumorigenicity46. 
Specifically in pancreatic cancer, oxidative balance is maintained through Kras-mediated 
regulation of  metabolic pathways47 as well as through other upregulated mechanisms that 




These observations show how imperative it is for a cancer cell to maintain optimal 
levels of ROS since high levels are known to promote cell death. Cancer cells meticulously 
achieve this oxidative balance at a tumorigenic “happy” medium through the upregulation 
of antioxidant mechanisms42. Disrupting this balance potentially provides a unique 
therapeutic window for selective cancer killing in pancreatic cancer.  Supporting this 
model, several studies have achieved selective killing of transformed cells through 
perturbation of redox status49-51, which is further validated by the approved use As2O3 
(Arsenic trioxide, Trisenox®) in the treatment of acute promyelocytic leukemia owing to 
its ability to inflict ROS-mediated cytotoxicity52. 
1.4 Cyst(e)ine depleting human enzyme 
Glutathione (GSH), a tripeptide made of cysteine, glycine and glutamate, is one of the 
major intracellular antioxidants. In cancer, GSH metabolism is known to impart protection 
from apoptosis and induce multidrug as well as radiation resistance53,54. Thus, 
therapeutically disrupting GSH metabolism could be effective either as a monotherapy or 
in combination with other anticancer agents. Buthionine sulfoximine (BSO), which inhibits 
de novo GSH synthesis by inhibiting the rate-limiting enzyme (glutamate-cysteine ligase) 
has been used at the laboratory bench for long a time but has not yet been approved for  use 
by the bedside possibly due to its toxic side effects55. Another feasible approach of 
decreasing glutathione synthesis is by depleting one of its three substrates. L-Cys, which 
contains the functional sulfhydryl moiety of glutathione, is readily synthesized by the 




GSH biosynthesis, the pool of intracellular L-Cys plays a critical role in maintaining redox 
homeostasis. Due to an increased demand for GSH and protein synthesis, proliferating cells 
need to supplement endogenous L-Cys synthesis by importing it from the extracellular 
space, where majority of L-Cys is in its oxidized form cystine (CSSC), which is 
immediately converted to L-Cys upon import57. This excessive requirement of L-
Cys/CSSC in cancer cells underlies our hypothesized selectivity factor afforded by our 
enzyme-mediated approach of depleting the extracellular cyst(e)ine (L-Cys and CSSC) 
pool. 
Our group has recently engineered a human enzyme, known as cyst(e)inase, that 
degrades both extracellular L-Cys and CSSC58. The enzyme is made by mutagenizing a 
human enzyme from the transsulfuration pathway, cystathionine-γ-lyase (CGL), whose 
native substrate is cystathionine, but also has a very low L-Cys and CSSC degrading 
activity. The final mutagenized product shows a lower specificity for cystathionine, and 
increased specificity for L-Cys and CSSC (Figure 1.1 a,b). The fact that cyst(e)inase is 
derived by introducing only two amino acid substitutions from a fully human enzyme 
(CGL) will minimize its immunogenicity, a problem faced by bacterial enzymes used in 
human therapy. A single 50 mg/kg dose of cyst(e)inase administered intraperitoneally (i.p.) 
in mice was able to completely deplete serum CSSC for 3 days (Figure 1.1 c). Clinical 
success with the asparagine-depleting bacterial enzyme Oncaspar® in treatment of acute 
lymphoblastic leukemia (ALL) underscores the feasibility of this enzyme-based approach. 
Moreover, our previous studies with cyst(e)inase showing marked reduction of growth of 





Figure 1.1 Cyst(e)inase is engineered to deplete extracellular CSSC and L-Cys. 
(a,b) The human enzyme cystathionine-γ-lyase (CGL) from the transsulfuration pathway 
is mutagenized at the indicated amino acid residues (a) to increase its specificity for its 
non-native substrates, CSSC and L-Cys (b). (c) A single 50 mg/kg intraperitoneal (i.p.) 
dose of cyst(e)inase depleted CSSC (left) and L-Cys (right) in mouse serum for 3 days. 
(d) Cyst(e)inase degrades both L-Cys and CSSC in the extracellular space ①. Normal 
tissues can synthesize L-Cys through the transsulfuration pathway ②. It can also be 
imported via xCT from the extracellular space, where most of it is in the oxidized state as 
CSSC (green arrow). Many cancers need to supplement L-Cys synthesis with 
extracellular import to support increased demands of protein and GSH synthesis. 
Cyst(e)inase, by depleting L-Cys/CSSC from the serum, reduces intracellular L-Cys 
availability, which leads to reduced GSH synthesis ③. The resulting oxidative stress 
leads to DNA damage and perturbation of redox sensitive protein signaling pathways ④, 
which are sensed by various stress-sensing proteins ⑤ that then lead to the induction of 




for the use of cyst(e)inase as a safe and effective cancer therapeutic option. We hypothesize 
that prolonged depletion of serum cyst(e)ine using cyst(e)inase will induce growth 
inhibitory and/or cytotoxic effects selectively in pancreatic cancer cells through a similar 
mechanism of action as observed in other cancer models58 (Figure 1.1 d).  
1.5 Drug combination analyses 
Gemcitabine, a deoxycytidine analog that causes premature termination during 
DNA replication, has remained the standard-of-care for pancreatic cancer for about two 
decades even though it produces only a modest increase of survival of around half a year59. 
Given the complex interplay between many growth-promoting and survival pathways that 
contribute to pancreatic cancer’s penchant for chemotherapeutic resistance, a better 
therapeutic strategy for combating this disease is by using multiple drugs in combination. 
While cyst(e)inase represents an excellent single-agent candidate for the treatment of many 
cancers including potentially pancreatic cancer, it is likely to be very useful in combination 
with other drugs as well. 
There have been a few notable combination therapies for pancreatic cancer that 
have translated their bench-side potential into bed-side results. Nanoparticle albumin-
bound (nab)-paclitaxel, an albumin-bound paclitaxel administered as a colloidal 
suspension, was found to potentiate the effects of gemcitabine by increasing the 
intratumoral concentration of gemcitabine in preclinical therapeutic trials60. Subsequently, 
a multicenter phase III clinical trial demonstrated the improved efficacy of this 




increase in survival in advanced PDAC to date has been achieved with FOLFIRINOX (a 
combination of folinic acid, 5-fluorouracil (5-FU), irinotecan and oxaliplatin) which 
increases survival to 11.1 months versus 6.8 months with gemcitabine; however, this highly 
toxic potpourri also has increased treatment-related toxicities, and is reserved only for 
patients with good performance 62.  
In our study, we will test combinations of different drugs with cyst(e)inase for any 
potential additive or synergistic effects. Knowing the major mechanism through which 
cyst(e)ine depletion leads to growth arrest/apoptosis will allow us to rationally design 
combination treatments that produce synergistic effects. Exploring the optimal balance 
among synergistic growth inhibition, greater bioavailability, and minimal toxicity might 
lead us to a candidate combination that is the most feasible for clinical development.  
1.5.1 Assessing synergy: Chou-Talalay method 
A synergistic effect is when two drugs exert a more than an additive effect. 
Similarly, the effect is antagonistic when the combined drugs exert a less than additive 
effect. However, this raises the question as to what really constitutes as additive. It cannot 
be just an arithmetic sum of effects, which would imply that two drugs that exert an 
inhibitory effect of 50% and 60% respectively exert a combined inhibition of 110% - a 
physically impossible result. Synergy is a pharmacological phenomenon that is most 
frequently quantified using an isobologram.  
Isobolograms can be constructed at different effect levels i.e., IC50, IC75 etc. To 
construct an IC50 (a concentration that inhibits cell survival 50% of control) isobologram, 





Figure 1.2 Quantifying drug interaction using the Chou-Talalay method. 
(a) The IC50 values for two drugs A and B are determined individually. (b) These IC50 
values make up the x and y-intercepts of the “line of additivity” on an IC50 (or ED50) 
isobologram. If combination treatment of A and B produces experimental points that fall 
below this line, then the drug combination is known to be synergistic; if the points fall 
above, the combination is antagonistic. (c) A constant-ratio drug combination experiment 
is performed by first calculating the ratio of the IC50s (denoted by k), and then 
combining the two drugs such that at every combination point, the ratio of doses is 
maintained at k. Since the IC50 value of the combination treatment represents a simple 
arithmetic sum of the two drug doses i.e., A+B = IC50(A+B), and also maintains the ratio 
B/A= k, the individual drug doses can be extracted from this IC50 value. These extracted 
doses plotted on the IC50 isobologram from (b) make up the “experimental point” for 
assessment of synergy/antagonism. (d) Alternately, a quantity called the Combination 
Index (CI) can be calculated for the drug combination at every experimental point using 




are plotted on the two axes and serve as the x and y-intercept for the straight line connecting 
these two points. Any experimental combination point that lies below this “line of 
additivity” is synergistic, anything that lies above is antagonistic (Figure 1.2b). 
Subsequently, a “constant-ratio” drug combination experiment between these two drugs is 
performed as follows. First, the ratio of the IC50 values of the two drugs is obtained –
suppose it comes out to be 300. Then, the drugs are combined at different doses such that 
every combination point has this fixed ratio – usually, a high dose of each (e.g., ~IC95) is 
used to make the first combination dose and every dose thereafter is obtained via serial 
dilution. After treating cells with these combinations for the desired time period, the IC50 
of the combination treatment is calculated (Figure 1.2c). This IC50 value is a sum of two 
drug concentrations, and when those individual drug concentrations are extrapolated, their 
ratio should be the same as the pre-determined ratio of individual IC50s (i.e., 300 in our 
example). Since there are two equations and two unknowns (the individual drug 
concentrations that make up the combination treatment’s IC50 value), a complete set of 
linear equations can be written to extrapolate the individual drug concentrations as follows, 
CA + CB = IC50AB 
CB / CA = 300 
CA and CB are individual drug concentrations that are combined at a constant ratio 
and produce IC50AB in combination. The point formed by (CA,CB) is then plotted on the 
IC50 isobologram, which determines if this specific two drug combination is synergistic. 
Synergy/antagonism at other effect levels (i.e., IC25, IC75) can be assessed using this same 
concept. 
On a similar note, to quantitatively assess the extent of drug interaction, a quantity 











CA,x and CB,x are the concentrations of drugs A and B used in combination to achieve 
x% effect. ICx,A and ICx,B are the concentrations of the same drugs used as single agents 
that achieve the same x% effect. CI values  less than 1, equal to 1 and greater than 1 indicate 
synergy, additivity and antagonism, respectively. Chou and Talalay were the first to 
introduce these principles of studying drug interactions and methods to quantify them63, 
which have now been adapted into a computer software called “Compusyn”64 that can 
calculate CI values as a function of affected fraction of cells (Fa), which can then be used 
to determine whether the combinatorial effect produced by two drug concentrations is 
synergistic or not (Figure 1.2d). 
Despite the convenience and popularity of the Chou-Talalay method, it has a few 
drawbacks. One, in this method, the concentration-effect curve (as shown in Figure 1.1a) 
is linearized by logarithmic transformation, a method which dates back to a period when 
investigators did not have access to nonlinear regression analytical tools and one that 
actually causes an underestimation of the steepness of the concentration-effect curves after 
transformation65. Secondly, this method requires well-established concentration-effect 
curves of the drugs as single agents64, which is time-consuming and also not always 
available i.e., in experiments that use only a few concentrations of the combined drugs.  
1.5.1 Assessing synergy: Bliss independence model 
A viable, alternate method of quantifying drug interaction when dose-response 
curves are nonstandard or unavailable is using the Bliss independence model66,67. This 




experimental time and resources by obviating the need to generate concentration-effect 
curves for single agents before a combination experiment. 
Suppose two drugs A and B are combined at concentrations a and b. If their 
individual inhibitory effect on cell/tumor growth (expressed as fraction affected relative to 
control) is Ia and Ib, respectively, the expected inhibitory effect of the combination can be 
calculated using the complete additivity of probability theory as 
Iab,exp = Ia + Ib - Ia × Ib 
The observed combined inhibitory effect, Iab,obs (derived from the actual drug 
combination experiment) is then compared with Iab,exp to make conclusions about the nature 












In addition, an isobologram plotting the Iab,exp and Iab,obs in the x and the y axis, 
respectively can be used to visually infer the extent of synergy achieved by two drugs as 
well as to compare the magnitude of synergy between multiple drug combinations in 
different cell lines68 (Figure 1.3). This method is especially useful in high-throughput 
screening settings where a large dose range for multiple drugs becomes impractical, and in 
situations where the dose-response curves for single agents cannot be modeled by the 
standard four-parameter logistic nonlinear regression curves66. In our studies of drug 






Figure 1.3 Assessing drug interaction using the Bliss model based isobologram 
Plotting the observed effect (obtained from an actual combination experiment) versus the 
expected effect (calculated using the Bliss method) of a two-drug combination is a 
convenient method to assess the extent of drug interaction from multiple drug-
combination experiments and to compare the effects of those combinations between 
different cell lines. Experimental data points that fall in the upper left region of the 




1.6 Dissertation outline: Exploring the gamut from in vitro to in vivo  
In our process of characterizing the efficacy of cyst(e)inase for pancreatic cancer 
therapy, we started our journey by exploring the effects of treatment in vitro in multiple 
pancreatic cancer cell lines. We used three pancreatic cancer cell lines, two of which had 
mutated KRAS (Panc1, KrasG12D and MIA-PaCa2, KrasG12C) and one had wild-type (WT) 
KRAS (BxPC3). After observing that MIA-PaCa2 and BxPC3 were more resistant to 
cyst(e)ine depletion, we delved deeper into the mechanistic underpinnings behind this 
phenomenon through which we uncovered the survival mechanisms employed by these 
resistant cells. This allowed us to rationally design drug combinations that constituted of 
inhibiting those survival pathways while concurrently treating with cyst(e)inase, which led 
to our discovery of several synergistic candidates for further preclinical study. We then 
moved on to demonstrate that our lead combination candidate, which provided the best 
potential for clinical translation, was able to recapitulate its in vitro synergistic effects in 
xenograft mouse models without any signs of systemic toxicity.  
1.6.1 Establishing the mechanism of action and cause for resistance 
As expected, cyst(e)inase caused a near complete depletion of intracellular L-Cys 
and GSH in all three cell lines; however, ROS-mediated apoptosis was seen in only Panc1 
cells. The other two “resistant” cell lines were able to halt proliferation and maintain 
survival under cyst(e)ine deprivation. As discussed earlier, when cells assume such a non-
proliferative phenotype, they have an increased tendency to channel their substrates into 
mitochondrial oxidative phosphorylation. Therefore, we explored the differences in 
mitochondrial metabolism between these cell lines. During cyst(e)inase treatment, MIA-




as well as electron transport chain function for ATP synthesis, which were compromised 
in Panc1. This hinted towards the fact that the ability to maintain mitochondrial fitness 
during cyst(e)ine deprivation is the cause for resistance. 
1.6.2 Rational design of drug combinations and isolation of lead candidate 
We therefore inhibited mitochondrial metabolism at different nodes, which 
sensitized the resistant cells to cyst(e)inase treatment. Since inhibitors of mitochondrial 
metabolism are unlikely to offer a wide enough therapeutic window, we hypothesized that 
cyst(e)inase will synergize with concurrent inhibition of alternate antioxidant mechanisms 
because maintaining a functional mitochondrial machinery imposes a liability of 
detoxifying ROS produced by the electron transport chain. As expected, inhibitors of other 
antioxidant pathways synergized with cyst(e)inase among which auranofin, an inhibitor of 
thioredoxin reductase and an approved drug for the treatment of rheumatoid arthritis, stood 
out as a lead candidate for further in vivo work due to its extreme synergy with cyst(e)inase 
and its high translational potential in a combination therapy regimen.  
1.6.3 In vivo validation  
Cyst(e)inase treatment of nude mice bearing pancreatic cancer xenografts mirrored 
the in vitro sensitivity profile: Panc1 cells exhibited the greatest inhibition of tumor growth 
while BxPC3 were completely resistant. Combining auranofin and cyst(e)inase inhibited 
growth of MIA-PaCa2 and BxPC3 xenografts without causing any overt signs of systemic 
toxicity. Our results that we describe herein provide a strong rationale for the further 
clinical development of cyst(e)inase and auranofin combination in the treatment of 




Chapter 2: Materials and Methods1 
2.1 Reagents  
CB-839, Quercetin, Myricetin (Selleckchem); Glutathione ethyl ester, Buthionine 
sulfoximine, Curcumin (Sigma); Tigecycline, Rotenone, Oligomycin (Cayman); UK5099 
(Tocris); Sulfasalazine (Fluka); Auranofin (Adipogen); L-aspartic acid 4-methyl ester 
hydrochloride (Alfa Aesar); Bafilomycin A1 (Sigma) were used. Ethaselen was kindly 
provided by Patrick Gunning from the University of Toronto.  
2.2 Cell lines and culture  
Human pancreatic cancer cell lines MIA-Paca2, Panc1 and BxPC3 were purchased 
from the American type culture collection (ATCC; Manassas, VA). Cell lines were 
confirmed to be mycoplasma free by PCR amplification (Applied Biological Materials 
Inc.) and 4,6-diamidino-2-phenylindole (DAPI) staining. Low passage cells (P<30) were 
cultured in either DMEM (MIA-PaCa2 and Panc1; Life Technologies) supplemented with 
10% fetal bovine serum (FBS; Life Technologies) and 1% penicillin/streptomycin 
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(Pen/Strep; Life Technologies) or RPMI-1640 (BxPC3; Life Technologies) supplemented 
with 10% FBS, 1% Pen/Strep, 1 mM sodium pyruvate (Corning) and 1 mM HEPES 
(Sigma). All cells were cultured at 37 ⁰C in 95% air and 5% CO2. Cystine deficient DMEM 
(Life Technologies, Cat. #21013024) and RPMI (Corning, Cat. #17104CI) were prepared 
by supplementing the base media with the aforementioned reagents and deficient nutrients 
except cystine.  
2.3 Western Blotting 
After treatment with indicated agents for the specified time, media was collected 
and centrifuged to pellet floating cells, and adherent cells were washed with PBS. Both cell 
fractions were combined and lysed in RIPA buffer with 1X protease and phosphatase 
inhibitor cocktails (Sigma). Protein concentration was quantified using DC Protein Assay 
(Bio-Rad) with bovine serum albumin (BSA) as a standard. Equal amounts of protein were 
separated on either fixed percentage or 4-15% gradient SDS-PAGE gels and transferred to 
0.45 mm nitrocellulose membranes (Bio-Rad). After blocking in 3% bovine serum albumin 
(BSA) for 30 min, membranes were probed with specific primary antibodies (listed below) 
overnight at 4 ⁰C and secondary antibody at room temperature for 2 hours. Membranes 
were visualized with chemiluminescent detection kits (SuperSignal West Pico, Thermo 
Scientific for stronger protein targets; WesternBright Quantum, Advansta for weaker 
ones).  
 The following primary antibodies were used for western blotting: p-JNKThr183/Tyr185 




riboSer235/236 (2211), S6 ribo (2217), p-RbSer807/811 (8516), Rb (9309), Cyclin D3 (2936), 
cdc25C (4688), p-AMPKThr172 (2531), AMPK (2532), xCT (12691), Thioredoxin 1 (2429), 
Thioredoxin reductase 1 (15140), Thioredoxin 2 (14907), Thioredoxin reductase 2 
(12029), c-jun (9165), Cleaved caspase 3 (9664), Cleaved caspase 7 (9491), LC3B (3868), 
p62 (8025), Hexokinase II (2867), pyruvate dehydrogenase (2784)  from Cell Signalling; 
Sestrin2 (sc-393195), Cyclin B1 (sc-752), Nrf2 (sc-13032), Cdk1 (sc-54), p27 (sc-776), 
succinate dehydrogenase-subunit A (sc-390381) from Santa Cruz Biotechnology; p-
ATMSer1981 (ab81292), GCL-C (ab53179) from Abcam; p-H2AXSer 139 (05-636, Millipore) 
and Actin (A5316, Sigma). 
2.4 Mouse studies 
For xenograft studies, one (MIA-PaCa2), two (BxPC3) or five (Panc1) million cells 
in a 200 µL solution of Matrigel (Corning) and serum free media (1:1) were injected 
subcutaneously into the hind flanks of 5-6 weeks-old athymic male nude mice (outbred 
homozygous Foxn1nu/ Foxn1nu; J:NU 007850, Jackson Laboratory). After tumor volumes 
reached a size of ~150 mm3 (as calculated using the formula 0.5 x l x w2, where l and w 
represent long and short diameters respectively, and are measured using a digital caliper), 
mice were divided into groups such that average tumor volumes in all the groups were 
approximately equal and treatment with indicated agents was begun as following: for 
single-agent cyst(e)inase studies, mice were given intraperitoneal (i.p.) injections twice a 
week with either 100 mg/kg cyst(e)inase or PBS. For combination studies, cyst(e)inase (50 




administered i.p. 3 times a week. Control mice were injected with PBS on cyst(e)inase 
treatment days and a 1:1 solution of 10% polyethylene glycol and 10% Tween80 in water 
(the solvent that was used to dilute 25 mg/mL DMSO-dissolved auranofin to make the 0.5 
mg/mL auranofin solution used for treatment). Mice were given a semi-purified diet 
(AIN76A, 10 kcal%, Research Diets) and water ad libitum. Body weight and food 
consumption of mice were measured triweekly and weekly respectively. Experiments were 
terminated when tumor sizes in the control group reached their maximum limit as specified 
by an approved protocol from the University of Texas at Austin Institutional Animal Care 
and Use Committee (IACUC). At study termination, blood was collected via cardiac 
puncture following euthanasia and assessed for liver and kidney function by measuring 
serum levels of alanine aminotransferase and urea respectively using commercially 
available kits (Sigma). 
2.5 Intracellular ROS measurement  
Cells were seeded at a density of 1 x 105 (3.5-cm dish) or 5 x 105 (6-cm dish) and 
allowed to attach for ~24 hours. Following treatment with different agents for indicated 
times, 2’,7’-Dichlorofluorescein diacetate (DCFDA, Sigma) for measuring total cellular 
ROS and MitoSOX Red mitochondrial superoxide indicator (Invitrogen) were added 
directly to the media at 20 µM and 2 µM final concentration respectively, and incubated at 
37 ⁰C for 30 min. Cells were trypsizined, resuspended in PBS and data were acquired by 





2.6 Cell viability, cell growth and cell death assay 
Cells were plated in 96-well plate at 5000 cells per well (100 µL). After ~24 h of 
attachment, cells were treated with 100 µL of different agents at 2X desired concentration 
for the indicated time points. At the end of treatment, media was aspirated and remaining 
viable cells were fixed with 10% formalin and stained with 0.05% crystal violet. After 
washing with water once, dye was extracted with 10% acetic acid and absorbance at 595 
nm was measured. Relative cell viability was computed by comparing absorbance to 
untreated or vehicle-treated cells. Cell growth was assessed by crystal violet staining as 
well. Briefly, 10-20 x 103 cells were plated in 3.5-cm dish and allowed to attach for 1-2 
days. At day = 0, one plate was stained with crystal violet as a surrogate measurement of 
cell number at the time of treatment. At every indicated subsequent time point, the relative 
cell number was calculated by measuring the fold change in crystal violet intensity relative 
to that at day = 0. Cell death was assessed by trypan blue exclusion test. Briefly, 2.5-5 x 
105 cells were plated at day = -1, treated with different agents at desired concentration at 
day = 0 and trypsinized after indicated time of treatment. Dead/floating cells were also 
collected. A 1:1 mixture of trypan blue dye (Bio-Rad) and the cell suspension of interest 
was counted using a hemocytometer or TC20 Automated Cell Counter (Bio-Rad) for live 
and dead (blue) cell count.  
2.7 Measurement of mitochondrial contents 
1 x105 cells were plated in 3.5-cm dishes and allowed to attach for ~24h. Following 




mass; Invitrogen) and MitoTracker Red CMXRos (for mitochondrial membrane potential; 
Invitrogen) were directly added to the media at 50 nM and 200 µM final concentration 
respectively. After incubation for 30 min at 37 ⁰C, cells were trypsinized and resuspended 
in PBS. Data were acquired by flow cytometry (Guava easyCyte 8HT, EMD Millipore) 
and analyzed with FlowJo software as previously described69. 
2.8 Intracellular glutathione measurement 
Following treatment of 1 x105 cells for 24 h, media was aspirated, cells were 
washed with PBS, and pelleted and mixed with 150 µL of 5% sulfosalicylic acid (Sigma). 
Cells were lysed via 2 cycles of freeze-thaw, cell debris was pelleted by centrifugation and 
the glutathione content in the resulting supernatant was measured using a glutathione 
detection kit (Sigma). Separate dishes that were treated in parallel were used to quantify 
protein content, which was then used for glutathione normalization. Alternately, 
intracellular glutathione content was also measured in a 96-well format using the 
GSH/GSSG-Glo Assay (Promega) following a 24 h treatment with normalization 
performed to viable cell count. 
2.9 Cell cycle analysis 
After treatment of 5 x105 cells with different concentrations of cyst(e)inase for 
indicated time points, adherent and floating cells were harvested, washed with PBS and 
fixed in ice-cold 70% ethanol at 20 ⁰C for 2-4 days. After fixation, cells were washed, 




ThermoScientific) and propidium iodide (PI; 40 µg/mL, Invitrogen) and incubated for 30 
min at 37 ⁰C. Data of cell-cycle phase distribution was acquired by flow cytometry and 
analyzed by FlowJo software. 
2.10 shRNA interference 
shRNA constructs were purchased from Origene. The lentiviral transduction 
particles used for gene knockdown in target cells were generated in HEK 293T cells. Gene-
specific shRNA plasmids are identified as follows: 
Thioredoxin reductase 1 (TXNRD1):  
shRNA #1: 5’-ACTATGACCTTATCATCATTGGAGGTGGC-3’,  
shRNA#2: 5’-AAGTCGAGGAGACAGTTAAGCATGATTGG-3’ 
Thioredoxin reductase 2 (TXNRD2):  
shRNA #1: 5’- CAGGCGAAGTTACTCAAGGATTTGCTCTG-3’,  
shRNA#2: 5’- GACACCAGAAGTCTGAATTTGGAGAAGGC-3’ 
Infected cells were incubated in media containing puromycin (0.2-1 µg/mL) for at least 48 
h before lysing cells for knockdown efficiency analysis or conducting further experiments. 
Puromycin was used for passaging knockdown cells but not during experiments with 
cyst(e)inase to avoid unforeseen combinatorial effects with puromycin. For double 
knockdown of TXNRD1 and TXNRD2, cells that were stably transfected with TXNRD2 
shRNA #1 were infected with viral particles containing TXNRD1 shRNA #2. Clones of 
cells harboring knockdown of both genes were obtained via multiple rounds of clonal 





2.11 Isobologram and evaluation of synergy 
To evaluate synergism between two compounds we used the Bliss Independence 
Model as previously described67,68. Briefly, the expected effect (Eexp) in a combination of 
two single agents is calculated from the effects of each separate agent as follows: 
Eexp = Eagent1 + Eagent2 – (Eagent1 × Eagent2) 
The Bliss index of a combination is the ratio of the observed effect to the expected effect 
with values =1, <0, or >1 indicating additivity, antagonism and synergy respectively. 
Experimental data points that fall in the upper left region of an isobologram showing 
correlation of observed vs expected effects indicate increasing level of synergy.  
2.12 Polar metabolite extraction and GC-MS analysis  
Cells were plated in 6-cm (5 x105 cells) dishes and allowed to attach for ~24 h. 
After treatment with cyst(e)inase in regular media for indicated timepoints, media was 
aspirated and cells were washed twice with 0.9% saline solution. Polar metabolites were 
extracted and analyzed by GC-MS as previously described30. Cells were scraped in 500 µL 
of HPLC grade methanol:water (1:1) solution, transferred to a tube and snap frozen in 
liquid N2 until further use. Cells were lysed via 3 cycles of freeze-thaw and cell debris was 
pelleted by centrifugation (14.8 x 103 rpm, 10 min, 4 ⁰C). The resulting supernatant was 
transferred to a glass vial, mixed with an equal volume of ice-cold chloroform, vortexed 




to a new tube and dried using SpeecVac concentration. Metabolites were derivatized by 
incubation at 37 ⁰C for 1 h in 20 µL of methoxyamine hydrochloride (Sigma, 20 mg/mL 
dissolved in pyridine) then in 30 µL of N-methyl-N-(trimethylsilyl)trifluoroacetamide with 
1% trimethylchlorosilane (Sigma) for another 1 h at 37 ⁰C. A small volume (0.2 µL) of 
derivatized samples were injected into a Thermo Scientific Trace 1310 gas chromatograph 
loaded with a Thermo TR-5 fused silica capillary column (length = 30 m, I.D. = 0.25 mm, 
film = 0.25 μm), which was connected to a Thermo ISQ single quadrupole mass 
spectrometer. Total ion current peaks of different metabolites were normalized to those of 
internal standard norvaline and isoleucine to control for differences in 
derivatization/injection and cell mass respectively.  
2.13 [U-13C]-glucose labeling  
Glucose that is 13C-labeled in all 6 carbons ([U-13C]-glucose) was purchased from 
Cambridge Isotope Laboratories. For all 13C labeling experiments, glucose and glutamine 
free DMEM (Life Technologies, Cat #A1443001) was supplemented with 25 mM [U-13C]-
glucose and 4 mM unlabeled glutamine, 10% dialyzed FBS and 1% Pen/Strep. Cells were 
plated at a density of 5 x 105 cells (6-cm dish) in regular media. After allowing ~24 hours 
for attachment, cells were treated with 13C-labeled media containing either vehicle (10% 
glycerol in PBS) or cyst(e)inase. After 6 h of treatment, polar metabolites were extracted 
and analyzed using gas chromatography-mass spectrometry (GC-MS) as mentioned above. 
The abundance of the following ions was used for analysis of 13C label incorporation: m/z 




isotopologue distribution for each metabolite was corrected for natural abundance of 13C 
using the software Metran40.  
2.14 Fluorescence microscopy for mitochondrial ROS 
Cells were plated at a density of 3-5 x 103 in 8-well cell culture chamber slides and 
allowed to attach for ~24 hours. After treatment for indicated time, MitoTracker Green FM 
was directly added to the media at 50 nM final concentration to stain mitochondria 30 min 
prior to the following steps. Media was dumped into a waste jar as opposed to aspiration, 
which caused cells to detach.  Cells were washed with PBS, the waste was dumped and 
any extra liquid on the slide was absorbed carefully using Kimwipes. A small volume of 
Vectashield mounting media containing DAPI (Vector Laboratories Inc.) was placed on 
each chamber and a glass cover slip was placed on top such that the media covered the 
entire chamber. Microscopy was performed with Olympus BX60 fluorescence microscope, 
and image acquisition was performed with the software DP Controller (Olympus).  
2.15 mCherry-GFP-LC3  
The plasmid (Addgene, plasmid #22418) was purified from E. coli and transfected 
into MIA-PaCa2 cells using Lipofectamine 3000 (Invitrogen). After 2-4 days, cells were 
incubated in media containing 1 µg/mL puromycin. Surviving cells expressing both green 
and red fluorescence were selected and expanded. Puromycin was used for passaging of 
transected cells but not during experiments. After treatment for indicated time, media was 




washed again with PBS. A small volume of Vectashield mounting media containing DAPI 
was placed on each chamber and a glass cover slip was placed on top. Microscopy was 
performed with Leica TCS SP5 II confocal microscope, and image acquisition was 
performed with the software Leica Application Suite (Leica Microsystems).  
2.16 Measurement of thioredoxin reductase activity  
Total thioredoxin reductase activity was measured in 15 μg of protein sample using 
a Thioredoxin Reductase Assay kit (Cayman) according to the manufacturer’s instructions.   
2.17 Measurement of NAD+/NADH   
Cells were plated in 96-well plate at 5000 cells per well (100 µL). After ~24 h of 
attachment, cells were treated with 100 µL of cyst(e)inase at 2X desired concentration for 
indicated time. At the end of treatment, NAD+/NADH was measured according to the 
NAD/NADH Glo Assay instructions provided by the manufacturer (Promega). Briefly, 
media was aspirated and replaced with 50 µL of PBS. Cells were lysed by adding 50 µL of 
0.2 N NaOH with 1% Dodecyltrimethylammonium bromide (DTAB) and shaking for 5 
min. 50 µL of this cell lysate was moved to a different well and treated with 25 μL of 0.4 
N HCl (acidic conditions selectively degrade NADH). NAD+ is selectively degraded in 
the basic conditions of the original wells. Plate was incubated for 30 min at 60°C, allowed 
to equilibrate to room temperature and then neutralized with 25 μL of 0.5 M Tris base 
(acid-treated wells) or 50 μL of 1:1 HCl/Tris solution (0.5 M Tris + 0.4 N HCl, base-treated 




NAD/NADH-Glo™ Detection Reagent, shaken for 2 h at room temperature and the 
luminescence was measured.  
2.18 Statistical analyses  
No statistical methods were used to predetermine sample size; selection of group 
sizes for animal experiments were driven by prior experience and literature precedence. 
The experiments were not randomized, and the investigators were not blinded during 
experiments or data analysis. Data are expressed as mean ± s.e.m. unless otherwise 
indicated and analyzed using GraphPad Prism 6. In xenograft experiments, outlier tumor 
values were identified and removed from all groups using the robust regression and outlier 
removal (ROUT) method with a 2% false discovery rate (FDR). Usage of the following 
statistical tests as applicable are described in figure legends: two-sided Student’s t-test, 
one-way ANOVA and two-way repeated-measures ANOVA followed by Bonferroni’s 
method for multiple-comparison test. Figure legends also describe the number of times 
experiments were repeated with similar results and the number of experiments that data is 















Chapter 3: Cyst(e)ine deprivation causes oxidative stress and apoptosis 
in sensitive cells but only growth arrest in resistant cells 
3.1 Introduction 
Following up on our work with cyst(e)inase in other cancer models58, we decided 
to assess the efficacy of this human enzyme in pancreatic cancer cells. As discussed in 
Chapter 1, our rationale for using this approach is that cancer cells strike an intricate 
balance between ROS and antioxidants to support proliferation, and tipping the scale 
towards ROS accumulation can cause selective oxidative demise of cancer cells. In 
pancreatic cancer cells, cellular growth has been shown to be intimately linked with ROS 
detoxification mechanisms, which provides further justification for our line of attack. 
Herein, we describe our rather surprising finding that cyst(e)inase mediated depletion of 
intracellular L-Cys and GSH leads to oxidative stress and cytotoxicity in only one out of 
the three cell lines tested. We delve into the mechanistic details behind the cytotoxicity 
observed in the “sensitive” cell line and the inhibition of cell growth induced in the more 
“resistant” cell lines, and provide segue for the next chapter with an idea for exploring the 
nexus of resistance.   
3.2 Results 
3.2.1 Oxidative stress and cell death induced in only Panc1 cells 
The three pancreatic cancer cell lines exhibited different levels of sensitivity to 
cyst(e)inase treatment (Figure 3.1 a) with Panc1 being the most sensitive while BxPC3 
were most resistant. Cyst(e)inase was able to deplete intracellular cysteine to low steady-





Figure 3.1 Cyst(e)inase causes oxidative stress and cell death in only Panc1 cells. 
(a) Relative cell survival 48 h after cyst(e)inase treatment in 3 pancreatic cancer cell lines 
(n = 3 cultures for each dose). (b) Intracellular L-Cys levels upon treatment with 250 nM 
cyst(e)inase (one treated and one untreated culture for each time point, data from a 
representative experiment). (c) Intracellular GSH levels 24 h after treatment (n = 3 cultures 
for each dose). (d,e) Cellular ROS levels as assessed by 2’,7’-dichlorofluorescin diacetate 
(DCFDA) fluorescence following a 24 h treatment (d; n = 3-5 independent experiments) 
and a 250 nM treatment (e; n = 3 technical replicates for each time point) with cyst(e)inase. 
tert-Butyl hydrogen peroxide (TBHP) treatment is included as a positive control for ROS 
accumulation (d). (f) Mitochondrial ROS levels as assessed by MitoSOX fluorescence 
following 24 h cyst(e)inase treatment (n = 3-6 independent experiments). (g) Oxidative 
stress signaling via JNK and ATM. Abbreviation: Cys, cyst(e)inase. (h) Cell death as 
assessed by trypan blue staining 48 h (Panc1) or 72 h (MIA-PaCa2 and BxPC3) after 
treatment (n = 3 independent experiments). (i) Cellular growth assay (n = 3 cultures for 
each time point). For g, “+” represents 250 nM cyst(e)inase treatment. All data represent 
mean ± s.e.m. except for b. *P < 0.05, ****P < 0.0001; compared to untreated controls; 




cysteine synthesis through the transsulfuration pathway probably does not account for 
resistance. As expected, cyst(e)inase mediated a complete depletion of intracellular GSH 
in all cell lines (Figure 3.1 c); however, only Panc1 cells exhibited accumulation of total 
cellular ROS (Figure 3.1 d,e) as well as  mitochondrial superoxide (mitochondrial ROS, 
Figure 3.1 f). BxPC3 were particularly resistant to ROS accumulation as even tert-Butyl 
hydrogen peroxide (TBHP) treatment did not cause any oxidative stress (Figure 3.1 d). A 
known consequence of oxidative stress in pancreatic cancer cells is activating 
phosphorylation of c-Jun N-terminal kinase (JNK)70, which was induced in Panc1 and 
MIA-PaCa2 cells by TBHP treatment but only in Panc1 cells by cyst(e)inase treatment 
(Figure 3.1 g). Another signaling event caused by ROS accumulation is through oxidative 
DNA damage, which activates the ataxia-telangiectasia mutated (ATM) protein kinase 
even in the absence of DNA double-strand breaks71. Again, activating phosphorylation in 
ATM was seen in only Panc1 cells after cyst(e)inase treatment (Figure 3.1 g). Downstream 
signaling through both of these stress-sensing kinases culminates in apoptotic cell death, 
which was corroborated by our finding that 250 nM cyst(e)inase caused more than 80% 
cell death in Panc1 within just 48 hours whereas no considerable cell death was seen in 
MIA-PaCa2 and BxPC3 cells (Figure 3.1 h). In fact, they were able to survive and maintain 
their cell mass even up till 96 hours of cyst(e)inase treatment (Figure 3.1 i). At initial 
glance, MIA-PaCa2 cells seem to be more sensitive to cyst(e)inase than BxPC3 (Figure 
3.1 a); however, both of them do not exhibit cell death upon extended treatment. The 
method used to generate the cell viability curve in Figure 3.1 a i.e., relative to control, 
causes MIA-PaCa2 cells to “appear” sensitive due to its significantly higher rate of 
proliferation compared to BxPC3 (Figure 3.1 i). In fact, if inhibition of cell survival in 
MIA-PaCa2 cells were to be assessed 72 hours after cyst(e)inase treatment, the relative cell 





Figure 3.2 Cystine deficient media recapitulates effects of cyst(e)inase in pancreatic 
cancer cells. 
(a) Relative cell survival of Panc1 and BxPC3 cells 48 h after cyst(e)inase treatment in 
indicated cell culture media (n = 3 cultures for each dose).  (b-d) Intracellular GSH levels 
(b; n = 3 cultures), cellular ROS levels (c; n = 4 independent experiments), and 
mitochondrial ROS levels (d; n = 3 independent experiments) 24 h after treatment with 
indicated media conditions. (e) Cell death 48 h after treatment with indicated media 
conditions (n = 2 independent experiments). All data represent mean ± s.e.m. ****P < 
0.0001; compared to untreated controls; two-way ANOVA with Bonferroni’s method for 




that of the sensitive Panc1 cells! However, since cyst(e)inase does not cause ROS 
accumulation and cell death in MIA-PaCa2 and BxPC3 cells, both of them will hereafter 
be considered cyst(e)inase resistant.  
3.2.2 Cystine-deficient media recapitulates effects of cyst(e)inase  
Since not all cell lines were cultured in the same type of medium (see Chapter 2.2), 
we wanted to investigate whether differences in culture medium played a role in 
determining sensitivity to cyst(e)inase. We found this not to be the case as Panc1 and 
BxPC3 did not change their sensitivity profile to cyst(e)inase treatment when cultured in 
the other cell line’s default medium (Figure 3.2 a). Cystine-deficient medium however 
perfectly recapitulated the effects of cyst(e)inase treatment as it caused a complete 
depletion of intracellular GSH in all three cell lines (Figure 3.2 b), but increase in ROS 
(total cellular as well as mitochondrial) and cell death in only Panc1 cells.  
3.2.3 Growth arrest in all cells and additionally apoptosis in Panc1  
Recently, our group showed that cyst(e)inase induces cell cycle arrest at G1 in 
multiple cancer models58. Specifically in pancreatic cancer cells, ROS is known to cause 
cell cycle arrest at the G2/M checkpoint following JNK activation70. In agreement with 
these findings, Panc1 cells, in which cyst(e)inase caused ROS accumulation and JNK 
activation, initially exhibited a G1 arrest (100nM) followed by a G2/M arrest and an 
apoptotic sub-G1 phase (250nM) after 24 hours of treatment (Figure 3.3a), whereas MIA-
PaCa2 and BxPC3 underwent only a G1 arrest (Figure 3.3a). Apoptotic signaling was 
initiated in Panc1 as early as 6 hours after cyst(e)inase treatment as evidenced by cleavage 






Figure 3.3 Cyst(e)inase induces cell cycle arrest in all cells but apoptosis in only 
Panc1 cells. 
(a) Quantification of cell cycle phase distribution 24 h after cyst(e)inase treatment (n = 3 
independent experiments). (b) Apoptosis signaling observed via cleavage of PARP 
following cyst(e)inase treatment. Abbreviation: Cys, cyst(e)inase. (c-e) Cell cycle phase 
distribution 48 h after cyst(e)inase treatment for Panc1 cells (c), and quantification of cell 
cycle phase distribution for Panc1 (d), MIA-PaCa2 and BxPC3 cells (e) 48 h after treatment 
(n = 3 independent experiments). (f) Regulatory cell cycle proteins following 24 and 48 h 
cyst(e)inase treatment. For b and f, “+” represents 250 nM cyst(e)inase treatment except 
for f, where “+” for Panc1-48 hrs represents 100 nM treatment. All data represent mean ± 
s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; compared to untreated 





two cell lines (Figure 3.3b). At 48 hours, the apoptotic sub-G1 phase in Panc1 cells 
accounted for 40% of cells even with the lower 100 nM treatment (Figure3.3 c,d) closely 
mirroring the magnitude of cell death seen in Panc1 cells when treated with that 
concentration for 48 hours (Figure 3.1h) indicating that apoptosis is the major mode of 
cell death caused by cyst(e)inase in sensitive cells. On the other hand, the two resistant cell 
lines still only exhibited only a G1 arrest with a subsequent failure to reach G2/M 
(Figure3.3 e), corroborating the absence of cell death in these cell lines (Figure 3.1h). Cell 
cycle proteins regulating the checkpoint for G1-S transition and G2-M transition decreased 
for all cell lines with treatment (Figure3.3 f). 
3.2.4 Inhibition of mTORC1 signaling in all cells 
Growth arrest following cyst(e)inase treatment could be a consequence of nutrient 
deprivation since L-Cys is also a substrate for protein synthesis. Mammalian cells have 
evolved two distinct amino acid sensing mechanisms – the mechanistic target of rapamycin 
complex 1 (mTORC1) signaling pathway is activated during amino acid replete conditions 
to stimulate protein synthesis while the general control nonderepressible 2 (GCN2) 
pathway is activated during amino acid starvation to inhibit protein translation. 
Specifically, GCN2, which is activated by uncharged tRNAs, links the deprivation of any 
single amino acid to inhibition of mTORC136. Activated GCN2 phosphorylates eIF2α, 
which globally inhibits cap-dependent protein translation except for the translation of a few 
stress response transcription factors including ATF4, which transcriptionally upregulates 
Sestrin2. Sestrin2 inhibits the lysosomal localization of mTORC1, which is needed for its 
activation and subsequent phosphorylation of its downstream target p70S6K (Figure 3.4a). 






Figure 3.4 Inhibition of mTORC1 signaling through the eIF2α-ATF4-Sestrin2 axis. 
(a) Schematic showing the pathway linking amino acid deprivation to inhibition of 
mTORC1 signaling. (b,c) Effect of cyst(e)inase (Cys) treatment on the eIF2α-ATF4-
Sestrin2 pathway (b) and mTORC1 signaling (c) Effect of treatment on AMPK signaling. 




the mTORC1 signaling pathway (Figure 3.4c) in all 3 cell lines. In the context of 
cyst(e)inase treatment, GCN2 signaling appeared more important than signaling through 
AMP kinase (AMPK), another known inhibitor of mTORC1, because sustained AMPK 
activation was observed in only Panc1 cells even though mTORC1 was inhibited in all 
three cell lines (Figure 3.4d). Since signaling through mTORC1 is intimately tied to 
cellular anabolism, the inhibition of this pathway provides a mechanistic link for the 
growth arrest observed with cyst(e)inase treatment in all three cell lines. However, due to 
the inhibition being present in all three cell lines, the difference in cyst(e)inase sensitivity 
between the lines begs a different mechanistic explanation. 
3.2.5 BSO does not recapitulate effects of cyst(e)inase 
To delineate the growth inhibitory effects of cyst(e)inase through GSH depletion 
versus nutrient deprivation, we treated these same cells with buthionine sulfoximine 
(BSO), a long-established inhibitor of GSH synthesis. Even though intracellular GSH was 
completely depleted by BSO within 24 hours in all 3 cell lines, cell survival was unaffected 
(Figure 3.5 a,b). BSO treatment induced cellular ROS (measured by DCFDA) in a manner 
that was different than that of cyst(e)inase or CSSC-deficient medium treatment (Figure 
3.5 c). More importantly, BSO treatment did not increase mROS in any of the three cell 
lines (Figure 3.5 d). Therefore, the growth inhibitory and cell killing effects of cyst(e)inase 
cannot be entirely explained by GSH depletion. 
3.3 Discussion  
These data show that cysteine/cystine depletion leads to growth inhibition of 






Figure 3.5 Buthionine sulfoximine (BSO) does not recapitulate all the effects of 
cyst(e)inase in pancreatic cancer cells. 
(a) Intracellular GSH levels 24 h after treatment (n = 3 technical replicates). (b) Relative 
cell survival 48 h after treatment (n = 3 cultures). (c) Cellular ROS levels 24 h after 
treatment (n = 2-3 independent experiments). (d) Mitochondrial ROS levels 24 h after 
treatment (n = 3-4 independent experiments). All data represent mean ± s.e.m. *P < 0.05, 
**P < 0.01, ****P < 0.0001; compared to untreated controls; two-way ANOVA with 




apoptosis in only one (Panc1) of out the three cell lines. A quite unexpected finding was 
that GSH depletion was not primarily the mechanism of cyst(e)inase mediated cytotoxicity. 
Cyst(e)inase caused a complete depletion of GSH in all three cell lines but induced ROS 
accumulation in only Panc1 cells. Buthionine sulfoximine (BSO), a well-known inhibitor 
of glutamate cysteine ligase (GCL), also caused a complete depletion of GSH but increased 
the total cellular ROS in a manner that was different than that induced by cyst(e)inase, 
which surprisingly had no effect on cell survival in any of the cell lines. More importantly, 
only cyst(e)inase and not BSO caused an increase in mitochondrial superoxide (mROS) in 
Panc1 cells implicating mitochondrially derived ROS as the major agent inflicting 
oxidative stress and mediating sensitivity to cyst(e)inase. Furthermore, a non-proliferative 
phenotype, as induced by cyst(e)inase in the other two “resistant” cell lines, requires 
changes in nutrient utilization that prioritizes mitochondrial oxidative phosphorylation 
over glycolysis9. Hence, exploring the differences in mitochondrial metabolism between 
the cell lines might uncover specific adaptations that promote resistance to cyst(e)inase. 
We can then utilize that knowledge to rationally design combination treatments sensitize 










Chapter 4: Maintaining mitochondrial fitness allows resistant cells to 
survive during cyst(e)ine deprivation 
4.1 Introduction 
 Altered metabolism is considered a hallmark of cancer11. Almost a century ago, 
Otto Warburg noticed the ability of tumor cells to rapidly convert glucose into lactate 
through glycolysis even in the presence of oxygen, now famously known as the Warburg 
Effect, and hypothesized mitochondrial dysfunction as a central tenet of cellular 
transformation. However, research in cancer metabolism over the last two decades has 
uncovered the indispensable nature of the biosynthetic and bioenergetic functions of the 
mitochondria in supporting cell survival and proliferation, which has deemed Warburg’s 
original hypothesis untenable12,72. Moreover, cancer cells are known to rely more on 
mitochondrial oxidative phosphorylation to maintain survival during nutrient limiting 
conditions9,73. Since the two cyst(e)inase-resistant cell lines are able to switch to a non-
proliferative phenotype and maintain survival during L-Cys/CSSC, we took the next 
logical step of exploring the mitochondrial metabolic network in these cell lines. In this 
chapter, we show that only the resistant cell lines are able to maintain biosynthetic and 
bioenergetic functions of the mitochondria during cyst(e)inase treatment, and concurrently 
inhibiting those functions leads to synergistic inhibition of cell survival.  
4.2 Results 
4.2.1 Cyst(e)inase causes anaplerosis defect in only Panc1 
 Within just 3 hours of cyst(e)inase treatment, there was a marked increase in 





Figure 4.1 Cyst(e)inase causes anaplerotic defect in only Panc1 cells. 
(a) Intracellular succinate abundance in MIA-PaCa2 and Panc1 cells 3 h after cyst(e)inase 
treatment. (b)TCA cycle intermediates and related metabolite levels 6 h and 24 h after 250 
nM cyst(e)inase treatment in MIA-PaCa2 and Panc1 cells (n = 3 cultures). (c,d) TCA cycle 
intermediates and related metabolite levels in BxPC3 cells (c; n = 3 cultures) and proline 
levels in all 3 cell lines (d; n = 3 cultures) 24 h after cyst(e)inase treatment. For b-d, color 




this increase was comparatively mild in Panc1 (Figure 4.1 a,b). Cyst(e)inase treatment in 
MIA-PaCa2 and Panc1 cells seemingly produces a blockade of the tricarboxylic acid 
(TCA) cycle at succinate dehydrogenase (SDH, Complex II), which catalyzes the oxidative 
conversion of succinate to fumarate using the electron acceptor FAD. A complete 
truncation of the TCA cycle without a mechanism to replenish pools of downstream 
metabolites cannot support cell proliferation because aspartate, which is derived from 
oxaloacetate (OAA) and contributes to nucleic acid and protein synthesis, is a limiting 
nutrient for cell proliferation25,26 (Illustration 4.1). Oxaloacetate in proliferating cells is 
generally derived via anaplerosis from glutamine27. However, cells that are deficient in 
SDH or cells that overcome glutamine dependence require upregulation of pyruvate 
carboxylase (PC) to replenish pools of aspartate29-31 (Illustration 4.1). The initial drop in 
aspartate levels following cyst(e)inase treatment eventually recovered in MIA-PaCa2 cells 
(to more than 50% of control) whereas it continued to drop in Panc1 cells (to less than 15% 
of control) (Figure 4.1 b). The blockade in SDH (indicated by succinate accumulation) 
was not seen in BxPC3 cells; concomitantly, they were also able to maintain aspartate 
levels at more than 50% of control upon cyst(e)inase treatment (data not shown and Figure 
4.1 c) most likely through glutamine dependent anaplerosis (further elaborated in Chapter 
4.2.2). Further supporting the fact that Panc1 cells became deficient in glutamine-
dependent anaplerosis after cyst(e)inase treatment was that proline, a glutamine derived 





Illustration 4.1 Schematic of nutrient utilization through the TCA cycle. 
Predicted induction of pyruvate carboxylase (PC) activity by MIA-PaCa2 cells to replenish 
pools of oxaloacetate (OAA) and subsequently aspartate (Asp) via [U-13C]-glucose. 
Abbreviations: Glc, glucose; Pyr, pyruvate; Lac, lactate; Ac-CoA, acetyl-CoA; Cit, citrate; 
α-KG, α-ketoglutarate; Glu, glutamate; Gln, glutamine; Succ, succinate, Fum, fumarate; 
Mal, malate; GLS, glutaminase; SDH, succinate dehydrogenase; ETC, electron transport 




4.2.2 Resistant cells maintain anaplerosis during L-Cys/CSSC deprivation 
As aforementioned, a truncation of the TCA cycle without a mechanism to 
replenish downstream metabolites is incompatible with cell survival and proliferation. We 
therefore compared induction of PC activity between MIA-PaCa2 and Panc1 cells upon 
cyst(e)inase treatment by culturing these cells in [U-13C]-glucose (glucose labeled in all 6 
carbons with 13C). Anaplerosis through PC, which catalyzes the carboxylation of glucose-
derived pyruvate to form oxaloacetate, is expected give rise to m+3 mass isotopologue 
(metabolite labeled with 13C in 3 of its carbons) in the aspartate pool as illustrated in 
Illustration 4.1. On the other hand, oxidation of pyruvate into acetyl-CoA through 
pyruvate dehydrogenase (PDH) and subsequent entry into the TCA cycle gives rise to m+2 
mass isotopologues in downstream metabolites. MIA-PaCa2 cells were able to recover 
their aspartate levels via anaplerosis through PC as evidenced by an increase in m+3 
fraction in aspartate and all the way to fumarate; this compensatory upregulation of PC 
activity was absent in Panc1 cells (Figure 4.2 a,b). The absence of cyt(e)inase-mediated 
SDH blockade in BxPC3 cells (Chapter 4.2.1) obviated the need for PC upregulation in 
these cells (Figure 4.2 c). Glutamine-dependent anaplerosis of the TCA cycle appeared 
unperturbed and enough to maintain aspartate levels in BxPC3 and consequently promote 
cell survival during L-Cys/CSSC deprivation, which was supported by two observations. 
First, the unlabeled (m+0) fraction of aspartate and fumarate in [U-13C]-glucose cultured 
cells, normally a surrogate measure of glutamine-dependent anaplerosis, was unchanged 
with cyst(e)inase treatment (Figure 4.2 c). Second, combining cyst(e)inase with CB-839, 
a glutaminase (GLS) inhibitor, produced a synergistic inhibition of cell survival (Figure 
4.2 d) in BxPC3 cells. Furthermore, the cyst(e)inase-resistant cells (MIA-PaCa2 and 






Figure 4.2 Anaplerosis through glucose and glutamine in resistant cells. 
(a,b) Mass isotopologue analysis of aspartate (a) and fumarate (b) in MIA-PaCa2 (top) and 
Panc1 cells (bottom) cultured in [U-13C]-glucose and treated with cyst(e)inase for 6 h (n = 
3 cultures). (c) Mass isotopologue analysis of aspartate (top) and fumarate (bottom) in 
BxPC3 cells cultured in [U-13C]-glucose and treated with cyst(e)inase for 6 h (n = 3 
cultures). (d) Cell survival of BxPC3 cells treated with combination of cyst(e)inase (Cys) 
and CB-839 for 48 h. Values are relative to untreated control, which is not shown (n = 3 
cultures for each condition). (e) Spheroid formation capacity assessed 3 days after plating. 
BxPC3 cells were cultured in both RPMI and DMEM. Scale bars, 100 μm. (f) Relative cell 
survival 48 h after treatment with either 200 nM Cys alone or in combination (single or 
double) with 0.5 mM GSH ethyl ester (GSH) and 5 mM methyl aspartate (Asp) (n = 3 
cultures). All data represent mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001; compared to untreated controls (a-c) or to Cys treatment (f); two-sided Student’s 






higher m+0 fraction in fumarate and aspartate (Figure 4.2 1 a-c). In addition, BxPC3 cells 
also appeared to have an increased capacity to rewire glutamine metabolism as evidenced 
by the fact that only these cells easily acquired anchorage independence and formed 
spheroids, a process that requires reductive carboxylation of glutamine-derived α-
ketoglutarate for maintenance of mitochondrial redox homeostasis74 (Figure 4.2 e). 
Supplementing cyst(e)inase with cell-permeable forms of GSH and aspartate as single 
agents rescued cell survival partially in all 3 cell lines but the two in combination 
augmented cell survival to untreated levels in MIA-PaCa2 and BxPC3 and near-untreated 
levels in Panc1 (Figure 4.2 f), bolstering our argument that GSH depletion is not the only 
mechanism through which cyst(e)inase mediates inhibition of cell survival. The 
mechanism of rescue with GSH ethyl ester in MIA-PaCa2 and BxPC3, in which 
cyst(e)inase did not induce oxidative stress, could be through normalization of redox 
sensitive protein signaling75 or cleavage of this GSH at the cell surface by gamma-glutamyl 
transpeptidase/transferase followed by passive diffusion of Cys-Gly-ethyl ester dipeptide 
inside the cell and subsequent hydrolysis to produce intracellular L-Cys76,77.  
4.2.3 Synergy through inhibition of mitochondrial metabolism 
To provide proof-of-principle that maintaining mitochondrial fitness is integral for 
acquiring resistance to cyst(e)inase, we attempted to concurrently inhibit mitochondrial 
metabolism at different nodes. Corroborating our previous finding that BxPC3 cells rely 
on glutamine metabolism to support cell survival during cyst(e)inase treatment, BxPC3 
were the most sensitive out of the three lines to concurrent glutaminase inhibition by CB-






Figure 4.3 Inhibition of mitochondrial metabolism synergizes with cyst(e)inase. 
(a,b) Isobologram of the effect of the combination of cyst(e)inase (Cys) and CB-839 (a), 
and Cys and UK5099 (b) (data from 2-4 independent experiments). (c) Intracellular ratio 
of NAD+/NADH 24 h after cyst(e)inase treatment (n = 3 cultures). (d) Isobologram of the 
effect of the combination of Cys and rotenone (data from 3 independent experiments). (e) 
Relative cell survival 48 h after rotenone treatment (n = 3 cultures for each dose). (f) 
Comparison of metabolic enzymes. “+” represents 250 nM cyst(e)inase treatment. (g,h) 
Isobologram of the effect of the combination of  Cys and oligomycin (g), and Cys and 
tigecycline (h) (data from 3-4 independent experiments). For c and e, data represent mean 




cyst(e)inase treatment, we concurrently blocked pyruvate transport into the mitochondrial 
matrix with the compound UK509928. Inhibiting mitochondrial pyruvate transport with 
UK5099 had a mild synergistic effect in all 3 cell lines (Figure 4.3 b), not only due to 
abrogation of PC activity but possibly also due to depletion of citrate, which is important 
for fatty acid synthesis (Illustration 4.1). We established in Chapter 4.2.2 that 
maintaining aspartate synthesis is an important factor for maintaining survival during L-
Cys/CSSC deprivation. A major requirement for the biosynthesis of aspartate is the proper 
functioning of the electron transport chain and maintenance of the NAD+/NADH ratio25,26. 
The depletion of aspartate seen with cyst(e)inase treatment only in Panc1 cells was not due 
to a perturbation of this ratio, and combining cyst(e)inase with rotenone (inhibitor of 
Complex I, which recycles NADH into NAD+) induced only a mild synergistic effect 
(Figure 4.3 c,d). It was notable however that MIA-PaCa2 and BxPC3 cells were more 
sensitive to rotenone treatment indicating that they have an increased basal reliance on the 
electron transport chain (Figure 4.3 e). Further supporting the idea that Panc1 cells cannot 
maintain mitochondrial metabolism during L-Cys/CSSC deprivation was that cyst(e)inase 
induced an increase in the glycolytic enzyme hexokinase with concomitant decrease in the 
mitochondrial enzymes pyruvate dehydrogenase (PDH) and succinate dehydrogenase-A 
(SDH-A) (Figure 4.3 f). There was no stark difference between the three lines in basal 
reliance on ATP synthase as probed by its inhibitor oligomycin (data not shown), but 
interestingly, MIA-PaCa2 and BxPC3 could be sensitized to cyst(e)inase through 
concurrent oligomycin treatment (Figure 4.3 g) corroborating the notion that a quiescent, 
non-proliferative phenotype requires oxidative phosphorylation9. The most compelling 
evidence for our mitochondrial fitness hypothesis is provided by the fact that tigecycline, 
an approved antibiotic that inhibits mitochondrial protein translation, produces a strong 




4.3 Discussion  
We have discovered here that resistance to cyst(e)inase is predicated on the ability 
to maintain mitochondrial function despite L-Cys/CSSC depletion. Specifically, resistant 
cells are able to sustain anaplerosis of the TCA cycle for aspartate synthesis and maintain 
ETC function for cellular bioenergetics. In MIA-PaCa2 cells, cyst(e)inase induced a block 
in SDH of the TCA cycle, which necessitated compensatory upregulation of PC activity 
for anaplerosis. The canonical route of anaplerosis through glutamine appeared 
unperturbed in BxPC3 cells. In the sensitive Panc1 cells however, cyst(e)inase induced a 
defect in glutamine-dependent anaplerosis that was not compensated by PC upregulation. 
Consequently, the aspartate levels in Panc1 cells fell to very low levels, which is consistent 
with the observation that cells that cannot utilize alternate fuel sources for anaplerosis 
during glutamine starvation are susceptible to ROS accumulation28. In Panc1 cells, 
cyst(e)inase reduced expression of SDH-A, which could explain the observed anaplerotic 
defect, as well as PDH. Interestingly, both of these mitochondrial flavoproteins, PDH and 
SDH-A, are known to be sites of ROS production78, yet their important bioenergetic role 
is highlighted by the fact that their loss can precipitate a progressive neurodegenerative 
disease called Leigh Syndrome characterized by dysfunctional mitochondrial energy 
production79,80. Concurrently inhibiting mitochondrial metabolism at different nodes 
produced synergistic inhibition of cell survival with cyst(e)inase treatment. These data 
suggest that perturbing the biosynthetic and bioenergetic functions of the mitochondria 
could be a viable approach to obtain synergy with cyst(e)inase, a strategy that we will build 





Chapter 5: Auranofin synergizes with cyst(e)inase by increasing 
mitochondrial ROS and inhibiting mitophagy 
5.1 Introduction 
In Chapter 4, we explored the differences in mitochondrial metabolism between 
Panc1 and the other two cyst(e)inase-resistant cells and discovered that the biosynthetic 
and bioenergetic functions of the mitochondria constitute synthetically lethal targets with 
cyst(e)inase. However, a caveat of this approach is that since mitochondrial functions are 
integral to the survival of non-cancerous cells as well, the therapeutic window that can be 
achieved through this strategy is likely very narrow. Indeed, strong inhibitors of the some 
parts of the mitochondrial respiratory complex (i.e., cyanide) are well-established lethal 
agents. Even tigecycline, which exhibited a high degree of synergy with cyst(e)inase in our 
studies, despite being an FDA-approved antibiotic, is used as a last-resort drug due to its 
unexplained higher mortality risk81. Alternately, complex I of the mitochondrial electron 
transport chain can be inhibited by metformin82, a biguanide anti-diabetic drug with an 
excellent safety profile; however, a stronger complex I inhibitor in rotenone produced only 
a mild synergistic effect with cyst(e)inase (Figure 4.3 d) indicating that complex I is likely 
not a very effective synthetic lethal target.  
Another approach at obtaining synergy with cyst(e)inase is concurrently inhibiting 
antioxidant pathways since maintaining mitochondrial function comes with the liability of 
detoxifying ROS, majority of which is produced by the ETC42.  In this chapter, we 
demonstrate that inhibiting alternate antioxidant pathways is an excellent approach of 





5.2.1 The thioredoxin system: a prime target for synergy  
Comparison of antioxidant pathways in the three cell lines indicated that basal 
levels of glutamate-cysteine ligase (GCL-C, enzyme involved in glutathione synthesis), 
cystine/glutamate antiporter (xCT) and thioredoxin1 were highest in BxPC3 (Figure 5.1 
a). Levels of the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a 
master regulator of cellular antioxidant response42 were also analyzed. Cyst(e)inase 
treatment caused induction of Nrf2 that was immediate and sustained in Panc1 but minimal 
in BxPC3 (Figure 5.1 b); hence Nrf2’s antioxidant response did not correlate with 
resistance to cyst(e)inase. Cystine deprivation is known to induce xCT in these particular 
cell lines83, which was recapitulated by cyst(e)inase treatment and as a result, the stark 
difference in xCT between the untreated cells was diminished (Figure 5.1 c). Such 
induction was not seen in GCL-C and thioredoxin1 (Figure 5.1 c). Concurrent inhibition 
of xCT with sulfasalazine produced synergy with cyst(e)inase in all three cells, but not as 
much as with inhibition of GCL using BSO (Figure 5.1 d,e). The lower synergy observed 
with sulfasalazine is probably due to the induction of xCT, which likely plays a protective 
role to some degree by facilitating increased cystine import. The synergy observed with 
BSO has a caveat as BSO is not yet approved for use in the clinic. We therefore turned to 
thioredoxin 1 whose expression pattern was especially striking because it was positively 
correlated with resistance to cyst(e)inase. Thioredoxins are antioxidant proteins that 
scavenge ROS by cycling between oxidized and reduced forms with the help of thioredoxin 
reductases. Mammalian cells have two major isoforms – a cytosolic thioredoxin 1 and a 
mitochondrial thioredoxin 2 that pair up with thioredoxin reductases 1 and 2 (TXNRD1 






Figure 5.1 Inhibition of alternate antioxidant pathways synergizes with cyst(e)inase. 
(a) Comparison of proteins related to antioxidant function in the 3 cell lines. Abbreviations: 
GCL-C, glutamate-cysteine ligase catalytic subunit; xCT, cystine/glutamate antiporter; 
TXNRD1 and TXNRD2, thioredoxin reductase 1 and 2 respectively. (b, c) Expression of 
antioxidant proteins following cyst(e)inase treatment. TBHP treatment (200 μM, 2 h) is 
included as a positive control for ROS accumulation (c). (d,e) Isobologram of the effect of 
the combination of cyst(e)inase (Cys) and sulfasalazine (d), and  Cys and BSO (e) (data 
from more than 3 independent experiments). (f) Cell survival of MIA-PaCa2 cells treated 
with combination of Cys and auranofin (Aur) for 48 h. Values are relative to untreated 
control, which is not shown (n = 3 cultures for each condition). (g) Isobologram of the 
effect of the combination of Cys and auranofin in MIA-PaCa2 and BxPC3 cells (data from 
more than 3 independent experiments). For b and c, “+” represents 250 nM cyst(e)inase 
treatment except for c, where “+” for Panc1-48 hrs represents 100 nM treatment. For f, data 





and is also an approved drug (Ridaura®) for the treatment of rheumatoid arthritis. As 
expected, auranofin treatment sensitized both of the resistant cell lines to cyst(e)inase 
(Figure 5.1 f,g). 
5.2.2 Auranofin and cyst(e)inase synergize through mitochondrial ROS 
As cytotoxicity induced by L-Cys/CSSC deprivation in Panc1 cells was specifically 
correlated with mitochondrial ROS (Chapter 3), we assessed mROS accumulation and 
oxidative stress signaling in the two resistant cell lines when treated with combination of 
cyst(e)inase and auranofin. The synergistic decrease in cell survival induced by 
combination treatment was paralleled with synergistic increases in mROS and cell death, 
which was rescued by supplementation with cell-permeable GSH (Figure 5.2 a). CSSC-
deficient medium combined with auranofin recapitulated the synergistic increase in cell 
death (Figure 5.2 b). Parameters of oxidative stress and DNA damage (activation of ATM 
and H2AX, and upregulation of c-Jun via activation of JNK) as well as markers of 
apoptosis (cleavage of ATM, PARP, and caspases 3 and 7) were increased by combination 
treatment and rescued by GSH supplementation (Figure 5.2 c). Moreover, growth-
promoting cell cycle checkpoint proteins (phosphorylated retinoblastoma, cdk1, cdc25C) 
were decreased and the inhibitory cell cycle protein p27 was increased by the combination 
of cyst(e)inase and auranofin (Figure 5.2 d). Mitochondrial ROS induced by the 
combination was capable of reaching the nucleus to cause the observed genotoxic effects 






Figure 5.2 Cyst(e)inase and auranofin combination treatment induces mROS and 
apoptosis in cyst(e)inase-resistant cells. 
(a) Relative mitochondrial ROS (mROS) levels (red) and cell death (black) in MIA-PaCa2 
(top) and BxPC3 (bottom) cells 24 h after indicated treatments. MIA-PaCa2: 50 nM Cys, 
0.5 μM (mROS) or 2 μM (cell death) Aur, BxPC3: 100 nM Cys, 2 μM (mROS) or 4 μM 
(cell death) Aur; 0.5 mM GSH ethyl ester (GSH) for both cell lines (for mROS, n = 5 
independent experiments; for cell death, n = 3 independent experiments). (b) Cell death in 
MIA-PaCa2 (top) and BxPC3 (bottom) cells 24 h after treatment with cystine (CSSC) 
deficient media, its combination with Aur (BxPC3: 4 μM, MIA-PaCa2: 2 μM) and the 
combination plus GSH (BxPC3: 0.5 mM, MIA-PaCa2: 1 mM) (n = 3 independent 
experiments). (c) Oxidative stress markers and apoptosis signaling in MIA-PaCa2 and 
BxPC3 cells treated with similar concentrations as in (a). (d) Regulatory cell cycle proteins 
24 h after the indicated combinatorial treatments in MIA-PaCa2 and BxPC3 cells. All data 
represent mean ± s.e.m. For a and b, ####P or ****P < 0.0001; compared to untreated 
controls (*, comparison done for Cys or no CSSC, Aur and Cys+Aur) or to Cys+Aur (#, 
comparison done for only Cys+Aur+GSH); one-way ANOVA with Bonferroni’s method 





Figure 5.3 Mitochondrial ROS induced by combination treatment of cyt(e)inase and 
auranofin reaches the nucleus. 
(a,b)  Representative images show mitochondrial ROS production in MIA-PaCa2 (a, 12 h 
treatment) and BxPC3 (b, 24 h treatment) cells labeled with MitoTracker Green and 




5.2.3 Inhibition of mitophagy and defective mitochondrial clearance 
We also investigated the effect of combination treatment on autophagy given its 
role in mitochondrial quality control and found an inhibition of autophagic flux as indicated 
by accumulation of both forms of LC3 protein as well as p62 (Figure 5.4 a). MIA-PaCa2 
cells transfected with mCherry-GFP-LC3 construct demonstrated that this autophagic 
defect is due to failure of autolysosome formation evidenced by an increase in 
colocalization of red and green fluorescence (yellow puncta), which was also seen in cells 
treated with Bafilomycin A1, an inhibitor of autophagosome and lysosome fusion85 
(Figure 5.4 b,c). This block in autophagy caused an accumulation of defective 
mitochondria that cannot maintain membrane potential (Figure 5.4 d-g), which are more 
prone to producing ROS69. Since GSH supplementation rescued this inhibition of 
mitophagy (Figure 5.4 a-g), ROS stress appeared to be the inciting event which supports 
the idea that the cyst(e)inase and auranofin combination is likely causing a vicious cycle 
of ROS stress and accumulation of defective mitochondria. In addition to oxidative 
damage, the loss of mitochondrial fitness abrogates the ability of cyst(e)inase-resistant cells 
to survive under L-Cys/CSSC deprivation. 
5.2.4 Thioredoxin reductase: the main target for synergy 
We next attempted to recapitulate these results with genetic inhibition of 
thioredoxin reductase. Surprisingly, knocking down thioredoxin reductases 1 and 2 
individually as well as concurrently had little or no combinatorial effect together with 
cyst(e)inase treatment (Figure 5.5 a-c). However, further analyses showed that a 
concentration of auranofin that reduces total thioredoxin reductase activity to the same 





Figure 5.4 Combination treatment of cyt(e)inase and auranofin inhibits mitophagy 
and causes accumulation of defective mitochondria. 
(a) Autophagy signaling 24 h after the indicated combinatorial treatments. (b) The doubly-
tagged mCherry-GFP-LC3 protein emits both red and green fluorescence (yellow when 
merged) from autophagosomes but only red fluorescence after fusion with lysosome due 
to quenching of GFP in the acidic environment of the autolysosome (c) Confocal 
microscopy images of mCherry-GFP-LC3-transfected MIA-PaCa2 cells 6 h after indicated 
treatments (Cys: 250nM, Aur: 0.5 μM, GSH: 2 mM, Bafilomycin A1: 10 nM; data from a 
representative experiment). Scale bars, 5 μm. (d) Mitochondrial mass was analyzed by 
labeling MIA-PaCa2 cells with MitoTracker Green. (e) Quantification of MitoTracker 
Green fluorescence after indicated combinatorial treatments for 24 h (n = 3-4 independent 
experiments). (f) Mitochondrial membrane potential (Δψm) was analyzed by labeling MIA-
PaCa2 cells with MitoTracker Green and MitoTracker Red. Gated population represents 
cells containing mitochondria with decreased membrane potential. (g) Quantification of 
cells with defective mitochondrial membrane potential after indicated combinatorial 
treatments for 24 h (n = 4 independent experiments). All data represent mean ± s.e.m. 
####P or ****P < 0.0001; compared to untreated controls (*, comparison done for Cys or 
no CSSC, Aur and Cys+Aur) or to Cys+Aur (#, comparison done for only Cys+Aur+GSH); 






Figure 5.5 Thioredoxin reductase is the synergistic target for auranofin but a near-
complete inhibition is required. 
(a,b) Relative cell survival 48 h after cyst(e)inase treatment in cells harboring shRNA-
mediated knockdown of thioredoxin reductase 1 (a) and thioredoxin reductase 2 (b) (n = 
3 cultures for each dose). (c) Relative cell survival 48 h after cyst(e)inase treatment in 
clones (cl.) of MIA-PaCa2 cells harboring shRNA-mediated double knockdown of 
TXNRD1 and TXNRD2 (n = 3 cultures for each dose). (d) Total thioredoxin reductase 
(TxnRD) activity in MIA-PaCa2 cells treated with auranofin for 24 h and in the double 
knockdown clones from (c) (n = 3 technical replicates for auranofin treated samples and n 
= 3-4 cultures per clone from two independent experiments). (e)  Relative cell survival 48 
h after cyst(e)inase treatment in MIA-PaCa2 cells treated concurrently with increasing 
concentrations of auranofin (n = 3 cultures for each dose). (f-h) Isobologram of the effect 
of the combination of cyst(e)inase (Cys) and ethaselen (f), Cys and curcumin (g), Cys and 
quercetin (h, half-filled symbols), and Cys and myricetin (h, solid symbols) (data from 2-





significant combinatorial effect with cyst(e)inase (Figure 5.5 d,e).  These data suggest a 
considerable redundancy in the thioredoxin antioxidant system. Additional evidence 
validating thioredoxin reductase as the major mechanistic target producing synergy in 
cyst(e)inase and auranofin combination was provided by the fact that synthetic 
(ethaselen86) as well as natural compound inhibitors (curcumin, myricetin, quercetin87,88)  
of thioredoxin reductase produced a synergistic inhibition of cell survival when combined 
with cyst(e)inase (Figure 5.5 f-h). 
5.3 Discussion  
We demonstrated in Chapter 4 that the cyst(e)inase-resistant cells were able to 
survive during L-Cys/CSSC deprivation by maintaining mitochondrial function, inhibiting 
which produced a synergistic effect with cyst(e)inase. Since the electron transport chain of 
the mitochondria is a major producer of ROS, we hypothesized that concurrently inhibiting 
alternate antioxidant pathways might also lead to synergy. As expected, auranofin as well 
as other inhibitors of antioxidant pathways synergized with cyst(e)inase in our studies. 
However, dual of inhibition of the GSH (using BSO) and the thioredoxin (using auranofin) 
antioxidant system to attain synergistic cancer cell killing is not a novel concept89. The 
novelty in our combinatorial approach lies in the mechanistic details.  
As described in Chapter 3, depletion of GSH is not the only mechanism through 
which cyst(e)inase mediates cell growth inhibition/apoptosis as BSO was able to 
recapitulate the former but not the latter. One important consequence of cyst(e)inase and 
auranofin combination is that in addition to causing an increase in mitochondrial ROS, it 
also induces a block in autophagic flux. Since one of the major functions of autophagy is 




accumulation of defective mitochondria, which has two cytotoxic effects that are not 
entirely mutually exclusive. First, the accumulation of mitochondria with defective 
membrane potential promotes accumulation of more mROS69. Second, the perturbation of 
mitochondrial metabolism abrogates the ability of cyst(e)inase-resistant cells to maintain 
the biosynthetic and bioenergetic functions of the mitochondria that promote survival 
during L-Cys/CSSC depletion. Since detoxifying the accumulated mROS via GSH 
supplementation was able to reverse the block in mitophagy, the inciting event that 
precipitates the block appears to be mROS stress. These observations support a model 
where the combination treatment causes a vicious cycle of mROS production and 
accumulation of defective mitochondria. 
Pancreatic cancers are known to have increased autophagic flux which helps them 
not only to maintain oxidative metabolism but also to control ROS levels, which makes 
autophagy inhibition a viable therapeutic target33,90. Since our combinatorial approach 
targets antioxidant mechanisms (GSH and thioredoxin) as well as blocks autophagy, which 
further exacerbates ROS accumulation and abrogates the resistance to cyst(e)inase 
imparted by a functional oxidative metabolism, this strategy is likely to prove very 
effective in vivo. In comparison, the combination of BSO and auranofin, even though 
extremely synergistic in vitro, might not be a very effective pharmacological approach at 
achieving dual inhibition of these antioxidant systems in vivo as this combination did not 









Chapter 6: Cyst(e)inase and auranofin synergizes in vivo 
6.1 Introduction 
To further assess the potential clinical relevance of these findings, we performed 
studies using xenograft models in mice. Intraperitoneally administered cyst(e)inase has 
already been shown to be a non-toxic yet effective therapeutic agent in multiple preclinical 
cancer models58. Herein, we show that the in vivo sensitivity to cyst(e)inase was similar to 
what was observed in vitro, with Panc1 being the most sensitive and BxPC3 being 
completely resistant. Further recapitulating our in vitro findings, adding auranofin to the 
treatment regimen sensitized the xenografts of resistant cell lines to cyst(e)inase without 
any signs of systemic toxicity. We conclude this chapter by presenting a model for the 
mechanism of action of cyst(e)inase as monotherapy as well as in combination with 
auranofin, and by presenting preliminary findings from in vitro triple-combination 
experiments that warrant further preclinical exploration.  
6.2 Results 
6.2.1 Sensitivity profile of cyst(e)inase recapitulated 
Biweekly intraperitoneal cyst(e)inase treatment (100 mg/kg) of male nude mice 
harboring pancreatic cancer xenografts mirrored the in vitro sensitivity profile: Panc1 
exhibited the most growth inhibition while BxPC3 xenografts were completely resistant 
(Figure 6.1 a-c). As we previously reported58, cyst(e)inase treated mice did not show any 
overt signs of toxicity as their body weight stayed constant for the duration of the treatment 





Figure 6.1 Sensitivity to cyst(e)inase is recapitulated in pancreatic cancer 
xenografts. 
(a) Growth of xenografted pancreatic tumors in male nude mice treated with cyst(e)inase 
(n = 8, 7 and 8 mice for Panc1, MIA-PaCa2 and BxPC3 respectively) or PBS control (n = 
7, 7 and 9 mice for Panc1, MIA-PaCa2 and BxPC3 respectively). (b) Average body 
weight of mice from BxPC3 xenograft experiment from (a). All data represent mean ± 
s.e.m. *P < 0.05, **P < 0.01, compared to PBS; repeated-measures two-way ANOVA 




6.2.2 Synergy with auranofin recapitulated without toxicity 
We next assessed whether the effectiveness of the cyst(e)inase and auranofin 
combination can be recapitulated in vivo. Much to our delight, co-administration of 
auranofin (3 mg/kg) and cyst(e)inase (100 mg/kg) markedly inhibited the growth of BxPC3 
xenografts whereas either agent alone had no significant effect (Figure 6.2 a). MIA-PaCa2 
cells were more sensitive to combination treatment than BxPC3 cells in vitro (Chapter 5), 
so a lower dose of cyst(e)inase was used for the xenograft combination experiment. 
Isobologram analysis based on the Bliss independence model showed that the 
combinatorial effects observed in MIA-PaCa2 and BxPC3 xenografts were both synergistic 
(Figure 6.2 b,c). Importantly, the combination did not produce any overt signs of systemic 
toxicity as body weight and food consumption did not decrease (Figure 6.2 d). Moreover, 
there was no increase in serum ALT (alanine aminotransferase) activity or urea 
concentration, markers of liver and kidney toxicity, respectively (Figure 6.2 e). 
Immunohistochemical analyses showed that the combination treatment produced focal 
areas of apoptotic cells (cleaved caspase 3) that exhibited reduced proliferation (Ki67) and 
reduced mitophagy (LC3 accumulation), which mirrored changes seen in cultured cells 
treated with the combination.  In contrast, tumor regions with cellularity as well as tumors 
from single-agent treatments did not differ significantly from vehicle treated tumors 
(Figure 6.2 f, data not shown).   
6.2.3 A working model and looking ahead 
In retrospect, we have demonstrated that cyst(e)inase-mediated L-Cys/CSSC 
depletion causes mROS accumulation and apoptosis in sensitive pancreatic cancer cells, 





Figure 6.2 Auranofin and cyst(e)inase synergistically inhibit growth of pancreatic 
cancer xenografts without toxicity. 
(a) Growth of xenografted BxPC3 pancreatic tumors in male nude mice treated with 
vehicle control (n = 8 mice), cyst(e)inase (n = 8 mice), auranofin (n = 8 mice), or 
cyst(e)inase and auranofin in combination (n = 7 mice), and waterfall plots indicating the 
percent difference from median tumor volume of vehicle treated group at day 42. (b) 
Growth of xenografted MIA-PaCa2 pancreatic tumors in male nude mice treated with 
vehicle control (n = 8 mice), cyst(e)inase (n = 8 mice), auranofin (n = 9 mice), or 
cyst(e)inase and auranofin in combination (n = 9 mice).  (c) Isobologram of the effect of 
the combination of cyst(e)inase (Cys) and auranofin on BxPC3 and MIA-PaCa2 
xenografts. (d,e) Average body weight (d, left), food consumption (d, right), liver 
toxicity as assessed by serum alanine aminotransferase (ALT) activity (e, left), and renal 
function as assessed by serum urea concentration (e, right) in mice from (a). (f) 
Representative immunohistochemical staining of xenografts from (a). Scale bars, 500 μm 
(Inset: 100 μm).  All data represent mean ± s.e.m. *P < 0.05, **P < 0.01, ****P < 
0.0001; compared to vehicle controls; repeated-measures two-way ANOVA (a,b) or two-






Figure 6.3 A working model and triple combinations with cyst(e)inase for future 
exploration. 
(a) Schematic showing basis for sensitivity to cyst(e)inase in pancreatic cancer cells. 
Cyst(e)inase-mediated depletion of intracellular L-Cys and GSH leads to apoptosis in 
sensitive cells through mitochondrial dysfunction, which is associated with ROS 
accumulation and reduced aspartate synthesis for anabolic metabolism. Resistant cells, on 
the other hand, survive this deprivation by maintaining oxidative metabolism to fuel their 
biosynthetic and bioenergetic demands, which necessitates detoxification of ROS 
produced by the electron transport chain (ETC) – a liability that can be clinically targeted 
by auranofin, a thioredoxin reductase (TXNRD) inhibitor. (b) Relative cell survival 48 h 
after cyst(e)inase treatment after indicated combinatorial treatments (n = 3 cultures for 
each condition). Values are relative to untreated controls, which is not shown but 
indicated by dashed line. Abbreviations: Cys or C, cyst(e)inase; Aur or A, auranofin; 





fitness. Consequently, inhibition of biosynthetic and bioenergetic functions of the 
mitochondria can sensitize resistant cells to cyst(e)inase treatment. Alternately, inhibiting 
other antioxidant defense mechanisms, which is required to detoxify ROS produced by the 
ETC, greatly synergizes with GSH-depletion by cyst(e)inase with the most striking 
combinatorial effect and high translational potential provided by auranofin, a specific 
inhibitor of thioredoxin reductase and an FDA-approved drug for rheumatoid arthritis. This 
is illustrated in (Figure 6.3 a). While concurrently inhibiting the GSH and thioredoxin 
antioxidant systems is already known to produce synergistic cell killing of cancer cells in 
vitro89,91, using BSO and auranofin to achieve this end in vivo might not be an effective 
therapeutic strategy91. Our current data demonstrate that co-administration of cyst(e)inase 
and auranofin can induce oxidative stress in multiple pancreatic cancer cells in vitro as well 
as in vivo, and has a favorable safety profile to justify further clinical evaluation. 
Furthermore, three-way combinations featuring cyst(e)inase, auranofin and additionally 
either BSO or the approved drug tigecycline produces synergistic inhibition of cell survival 
in vitro when compared to either agent alone or two-way combinations (Figure 6.3 b). It 
remains to be seen whether this synergy can be translated to mouse models without 











Chapter 7: Concluding Remarks 
 Cancer cells channel available nutrients in the serum such as glucose, glutamine 
and amino acids into distinct metabolic routes to support a rampant, proliferative program. 
Their biosynthetic and bioenergetic requirements are vastly different from non-
proliferating, differentiated tissue, which leads to their exquisite dependence on certain 
nutrients. This differential requirement in cancer versus normal cells makes depletion of 
specific nutrients an exciting therapeutic approach. Under the umbrella of this strategy, 
amino acid depletion is a clinically tested modality as demonstrated by the successful use 
of the asparagine-depleting enzyme, asparaginase, as part of a combination therapy against 
pediatric acute lymphoblastic leukemia (ALL). However, the bacterial origin of this 
enzyme makes it very immunogenic, which leads to a panoply of side effects92.  
 A superior approach is to use a human enzyme that is genetically engineered to 
degrade specific nutrients, which brings us to cyst(e)inase. This enzyme is generated via 
substitutions of just two amino acid residues in the human cystathionine-γ-lyase (CGL), 
which imparts unto the new enzyme an ability to degrade extracellular L-Cys and CSSC 
(collectively referred to as cyst(e)ine). Depletion of extracellular cyst(e)ine provides a wide 
enough therapeutic window due to cancer cells’ increased demand for L-Cys that is not 
sufficed by intracellular synthesis and hence necessitates import from the extracellular 
space. This is demonstrated by the ability of cyst(e)inase to mediate growth inhibition of 
multiple tumor types. Furthermore, its remarkable safety profile evident in the absence of 
any significant toxicity even with treatment for over 5 months speaks volumes of its high 
translational potential58.  
Extending this exploratory work into the pancreatic cancer model, we discovered 




treatment. We demonstrated that a cell’s ability to evade the cytotoxic effects of cyst(e)ine 
depletion is correlated with its ability to maintain mitochondrial fitness. However, this is 
also a double-edged sword for the cell because a functional electron transport chain, the 
major producer of cellular ROS, demands an arsenal of antioxidants to combat potential 
oxidative stress. Consequently, the thioredoxin antioxidant system becomes a liability for 
resistant cells during cyst(e)ine starvation, which forms the basis of synergy achieved by 
combining cyst(e)inase with auranofin, an inhibitor of thioredoxin reductase. 
There are several important translational implications of our findings. Clinical 
precedence with monotherapy in pancreatic cancer taken together with our results point 
towards the fact that cyst(e)inase is unlikely to prove efficacious as a single-agent, 
especially considering the fact that most pancreatic tumors requiring chemotherapy are 
advanced and harbor multiple genetic alterations that impart chemotherapeutic resistance. 
Here, we have identified the thioredoxin system as a synthetic lethal target with 
cyst(e)inase, which can be exploited with auranofin combination therapy to treat pancreatic 
cancers with various genetic alterations. Notably, auranofin, an FDA-approved drug for 
the treatment of rheumatoid arthritis, produced no systemic toxicity when combined with 
cyst(e)inase providing a strong rationale for advancing this drug combination further down 
the clinical development pipeline.  Future exploration into other resistance mechanisms 
and identification of additional liabilities can guide better combination therapy options. For 
example, our preliminary data shows that a triple combination treatment of cyst(e)inase, 
auranofin and either BSO or tigecycline has a greater effect in cell survival inhibition than 
two drug combinations, a finding that is sure to spark interest for elucidating the 
mechanistic underpinnings behind this observation and for in vivo validation. 
However, investigating the clinical efficacy of such combinations requires the 




development such as circulatory persistence of each drug, effective drug concentration 
within the tumor, off-target effects leading to systemic toxicity etc. For example, pancreatic 
tumors are known to have a highly desmoplastic and hypovascular microenvironment, 
which makes drug-delivery an arduous task. Concomitantly, combining gemcitabine with 
an inhibitor of the Hedgehog signaling pathway to deplete tumor-associated stromal tissue 
enhanced the anti-tumor effect of gemcitabine93. Since depletion of cyst(e)ine from the 
serum is how cyst(e)inase exerts its anti-tumor effect, the problem of drug-delivery is 
circumvented; however, other combinatorial agents have to pass through this extra layer of 
consideration. Similarly, drugs that have lower circulatory persistence due to increased 
renal filtration cannot reach the tumor site in effective concentrations to exert their effects. 
In one of our in vivo experiments, the batch of cyst(e)inase that we were using was 
incompletely PEGylated – a fact that we discovered retrospectively when that experiment 
did not work. Switching to a well PEGylated batch resolved this problem demonstrating 
the importance of avoiding immediate renal clearance for a drug’s in vivo efficacy. Another 
obstacle is systemic toxicity, which has to be carefully monitored. The greatest increase in 
survival (11.1 months) in pancreatic cancer to date has been achieved by the combination 
regimen in FOLFIRINOX, but it is also associated with more toxic side-effects94.  
An important issue that remains to be explored is the role of the tumor 
microenvironment in this context, and how we can use that knowledge to our benefit. It 
has been recently shown that pancreatic stellate cells recycle their intracellular contents 
through autophagy and “feed” the resulting nutrients, most notably alanine, to pancreatic 
cancer cells to support their growth95.  A strategy to inhibit this cross-talk will likely 
enhance the effects seen with our amino acid depleting approach. Investigating the immune 
aspects of the microenvironment will also open up avenues for potential combinations with 




of exogenous cyst(e)ine, and the inhibition of T-cell mediated anti-tumor immunity 
observed in many cancer cells is thought be caused by the depletion of cyst(e)ine by 
myeloid-derived suppressor cells96,97. Significant immune defects were not seen even with 
long-term cyst(e)inase treatment58, but still the questions of whether anti-tumor immunity 
is blocked to some extent by cyst(e)inase, and whether synergy can be achieved with 
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